Next Article in Journal
Effect of Titanium and Zirconia Nanoparticles on Human Gingival Mesenchymal Stromal Cells
Previous Article in Journal
Phenotypic and Transcriptional Changes of Pulmonary Immune Responses in Dogs Following Canine Distemper Virus Infection
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 17
10.3390/ijms231710020
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Protective Effects of Flavonoids against Alzheimer’s Disease: Pathological Hypothesis, Potential Targets, and Structure–Activity Relationship

by
Jiao Li
1,*,
Min Sun
1,
Xiaodong Cui
2 and
Chen Li
1,*
1
School of Life Science, Shanxi University, Taiyuan 030006, China
2
Institute of Biotechnology, Shanxi University, Taiyuan 030006, China
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(17), 10020; https://doi.org/10.3390/ijms231710020
Submission received: 17 July 2022 / Revised: 22 August 2022 / Accepted: 26 August 2022 / Published: 2 September 2022
(This article belongs to the Section Bioactives and Nutraceuticals)
Browse Figures
Review Reports Versions Notes

Abstract

:
Alzheimer’s disease (AD) is a neurodegenerative disease with high morbidity and mortality, for which there is no available cure. Currently, it is generally believed that AD is a disease caused by multiple factors, such as amyloid-beta accumulation, tau protein hyperphosphorylation, oxidative stress, and inflammation. Multitarget prevention and treatment strategies for AD are recommended. Interestingly, naturally occurring dietary flavonoids, a class of polyphenols, have been reported to have multiple biological activities and anti-AD effects in several AD models owing to their antioxidative, anti-inflammatory, and anti-amyloidogenic properties. In this review, we summarize and discuss the existing multiple pathogenic factors of AD. Moreover, we further elaborate on the biological activities of natural flavonoids and their potential mode of action and targets in managing AD by presenting a wide range of experimental evidence. The gathered data indicate that flavonoids can be regarded as prophylactics to slow the advancement of AD or avert its onset. Different flavonoids have different activities and varying levels of activity. Further, this review summarizes the structure–activity relationship of flavonoids based on the existing literature and can provide guidance on the design and selection of flavonoids as anti-AD drugs.

Graphical Abstract

1. Introduction

Alzheimer’s disease (AD), commonly known as senile dementia, is the main type of dementia and is an age-related neurodegenerative disease. The incidence of AD gradually increases with age, and the incidence rate can be as high as 50% in individuals over 85 years old [1]. With the aging of the global population, the number of patients with AD inevitably increases. According to the statistics reported by the World Health Organization, at the end of 2019, more than 50 million people worldwide suffered from AD. The total number of patients with AD globally is estimated to reach 82 million in 2030 and 152 million in 2050. In 2015 alone, the global treatment and care costs associated with AD were USD 957.56 billion, and this figure is estimated to reach USD 2.54 trillion in 2030 and USD 9.12 trillion in 2050 [2]. Despite this significant public health issue, only five medical treatments have been approved for the management of AD. After nearly 20 years, the United States Food and Drug Administration approved aducanumab (Aduhelm), a new drug, for the treatment of AD on 7 June 2021. Among the therapies approved for AD in the United States, this is the first and the only currently used drug to treat AD and not simply alleviate its symptoms. However, current evidence on the effectiveness of Aduhelm is not strong.
At present, there is no clear conclusion on the pathogenesis of AD, but it is generally believed that AD is a disease caused by multiple factors. These factors work synergistically to cause the occurrence and development of AD. It is unlikely that targeting a single change will be effective for disease treatment. Thus, compounds with multiple biological activities that can impact various AD-associated changes that contribute to disease development and progression are needed. An excellent source for multitarget compounds is the original pharmacopeia—plants. Plants can synthesize a huge array of compounds called secondary metabolites, which are not required for plant growth. Among these plant-derived secondary metabolites, flavonoids have been specifically highlighted in several epidemiological studies for their potential role that benefits the prevention of AD. For example, a Mediterranean diet rich in flavonoids might slow age-related cognitive decline and reduce the risk of dementia [3]. Population studies on the correlations between flavonoid intake and dementia in 23 developed countries found that increased consumption of dietary flavonoids, especially flavonols, is associated with lower rates of dementia in the population of those countries [4]. Consistent with these results, a large cohort study based on a random sample of 1367 subjects aged 65 years and higher found that the intake of foods rich in flavonoids is inversely correlated with the risk of the incidence of dementia [5]. Although direct clinical evidence is lacking, the potential effect of flavonoids in the management of AD has been analyzed in some reports. Teles et al. [6] systematically reviewed the preclinical evidence of flavonoids in treating AD. Hole et al. summarized the progress and adverse effects of flavonoids in treating AD [7]. Uddin et al. [8] elaborated on the therapeutic promise of flavonoids in the management of AD through various signaling pathways. Hongjun Xia et al. [9] reviewed the metabolism of flavonoids and their bioactive metabolites and the underlying mechanism to reverse AD pathology. In this review, we summarize and discuss the existing hypotheses in the pathogenesis of AD, including THE neglected “the infectious theory”. Accordingly, we explored the potential mode of action of flavonoids used in the management of AD and the mechanisms underlying their activities, including experimental evidence AND potential targets. Further, the potential benefits of many individual flavonoids such as catechins [10], quercetin [11], apigenin [12], nobiletin [13], fisetin [14], and chrysin [15] in treating AD have also been described in some reviews. These papers show different flavonoids have different activities and levels of activity. Thus, in this review, we summarize the structure–activity relationship of flavonoids based on the existing literature.

2. AD and Current Hypotheses on AD

AD is a progressive neurodegenerative disorder. With the development of AD, the memory of affected individuals declines, and their cognitive function is impaired. Patients eventually develop dementia and lose their self-care ability. AD was first reported by Alois Alzheimer in 1907, and the disease was named after him [16]. Alois Alzheimer described two typical pathological injuries in the brains of patients with AD: neurofibrillary tangles (NFTs) in nerve cells and the formation of senile plaques outside the nerve cells. The main component of NTFs is the abnormally hyperphosphorylated microtubule-associated protein (tau), which exists in the form of aggregated double-helical filaments. Senile plaques are mainly formed by abnormal folding and aggregation of amyloid-beta (Aβ). Although these two pathological occurrences have always been used as diagnostic indicators of AD, many controversies about the pathogenesis of AD continue to exist [17]. Several overlapping mechanisms have been proposed to explain the underlying pathology of AD, and both current and future potential treatments are based on the modification of these mechanisms.

3. Amyloid Cascade Hypothesis

The “amyloid cascade hypothesis” is the most classic hypothesis elucidating the pathogenesis of AD. This hypothesis suggests that the deposition of Aβ protein, the main component of plaques, is the causative agent of AD [18]. Aβ is a polypeptide consisting of about 42 amino acids, and it is formed by the sequential cleavage of Aβ precursor protein (APP) by β-secretase (β-amyloid cleaving enzyme 1, BACE1) and γ-secretase, which is also found to be the main cleavage pathway of APP in individuals with AD [19,20]. Aβ has a strong self-aggregation propensity and can thus easily form the Aβ oligomer and deposits, all of which are cytotoxic [21,22]. They can trigger a cascade leading to synaptic damage and neuron loss and ultimately to the pathological hallmarks of AD, which are amyloid plaques and NFTs consisting of hyperphosphorylated tau protein [23].
The “amyloid cascade hypothesis” cannot comprehensively explain the neuronal damage in AD due to several reasons [24]. For example, amyloid deposition can be found in cognitively normal elderly subjects, and treatments that reduce Aβ load do not modify the progression of AD both in animal and human models [25]. Nevertheless, many AD research communities still believe that Aβ is the most basic component for the occurrence of AD and acts as a trigger for other pathogenic factors [26,27] Thus far, aducanumab is the first Aβ-targeting drug that has received approval for the treatment of AD.

4. Tau Hypothesis

The tau hypothesis supports that the principal causative substance of AD is tau protein. Tau is a phosphoglycerate protein that contains 2–3 phosphate groups and is expressed in neurons that normally function in the stabilization of microtubules in the cell cytoskeleton [28]. The tau protein content in the brains of patients with AD is about 3–4 times that in healthy individuals. Moreover, tau protein is abnormally hyperphosphorylated, and each molecule of tau protein in patients with AD can contain 5–9 phosphate groups [29]. Hyperphosphorylation causes the tau protein to accumulate as NFT masses within nerve cell bodies. This is a major pathological feature of AD in addition to Aβ deposition. These tangles then aberrantly interact with cellular proteins, preventing them from executing their normal functions. Clinically, the degree of phosphorylation of tau protein has a positive correlation with the severity of AD [30]. The tau hypothesis also suggests that tau lesions occur prior to Aβ accumulation.

5. Oxidative Stress Hypothesis

Oxidative stress is another common pathological feature of AD [31]. Compared with other aerobic tissues and organs, neurons of the brain are more prone to oxidative stress due to several reasons. First, the brain, a component of the central nervous system, consumes more oxygen, which leads to increased ROS production [32]. Second, the intrinsic antioxidant defense of the neurons of the brain is weak [33] because they have low levels of antioxidant enzymes or compounds, such as superoxide dismutase, peroxidase, and glutathione. Additionally, antioxidants in other body parts cannot easily cross the blood–brain barrier (BBB). Moreover, the cell membranes of neurons in the brain contain high levels of unsaturated fatty acids, which are prone to react with free radicals through peroxidation reactions [34,35]. ROS accumulates in the neurons of the brain, causing neurotoxicity and neuronal synaptic dysfunction. In AD, Aβ aggregation, tau phosphorylation, metal ion accumulation, and inflammatory response can stimulate excessive production of ROS and damage the antioxidant defense ability, causing oxidative stress [36,37,38].

6. Inflammation Hypothesis

Over the past decade, evidence has indicated that reactive gliosis and neuroinflammation are the hallmarks of AD [39,40,41,42]. Immunohistochemical experiments have shown that inflammatory markers such as acute phase proteins, complement, and activated microglia are detected in the brain tissues of patients with AD. Proinflammatory and anti-inflammatory cytokines (eotaxin, interleukin (IL)-1ra, IL-4, IL-7, IL-8, IL-9, IL-10, IL-15, granulocyte colony-stimulating factor, monocyte chemotactic protein 1, platelet-derived growth factor, tumor necrosis factor (TNF)-α) have also been found to increase in the serum and brain tissues of patients with AD [43,44,45,46,47]. Upregulation of anti-inflammatory cytokine levels plays a “protective” role in AD [46]. As an inflammatory-stimulating factor, Aβ protein in the brains of AD patients can activate astrocytes and microglia to release inflammatory factors with strong neurotoxicity, including nitric oxide, TNF, and complement Cl and C3 [48]. Overexpression and the complex interaction of these factors can lead to inflammation and promote the generation of free radicals, which can damage neuronal cells [49]. Apart from their direct neurotoxic effects, proinflammatory cytokines can activate β-secretase to promote Aβ deposition [50,51]. Several studies in mouse models have shown that the level of amyloid deposition is increased under inflammatory conditions [52].

7. Cholinergic Hypothesis

The cholinergic hypothesis has been proposed to describe the pathogenesis of AD earlier and is one of the currently and widely accepted hypotheses [53]. Acetylcholine (ACh) is an important neurotransmitter used by cholinergic neurons for many critical physiological processes such as cognition and memory [54,55]. Cholinergic neurons in the normal basal forebrain can synthesize a large amount of ACh. However, in the brains of patients with AD, a large number of cholinergic neurons are lost, and the activity of choline acetyltransferase is reduced, resulting in a significant reduction in the synthesis, storage, and release of ACh. Cholinergic neuronal damage is considered a critical pathological change that is correlated with cognitive impairment observed in AD. Aβ accumulation, hyperphosphorylation of tau protein, oxidative stress, inflammation, and metal imbalance cause cholinergic neuronal damage. The first drug approved for the treatment of AD was tacrine, a cholinesterase inhibitor. However, the drug was withdrawn from the market in 2012, as it resulted in severe side effects. Thus far, acetylcholinesterase (AChE) inhibitors are the most widely used drugs in the clinical treatment of AD [56,57,58,59,60].

8. Metal Ion Hypothesis

Studies have shown that the balance of metal ions, especially zinc, iron, and copper, in patients with AD is disrupted, causing them to be redistributed in the brain. Post-mortem analyses of patients with AD have revealed the accumulation of copper, iron, and zinc to be 5.7, 2.8, and 3.1 times higher, respectively, than that observed in normal brains [61,62]. The breakdown of ion distribution balance can lead to an imbalance of metal protein. The metabolic disorder of metal ions in the cerebral cortex and hippocampus can cause the accumulation and aggregation of Aβ. Free metal ions with reducing properties (such as Fe2+ and Cu+) can also be combined with reactive oxygen ions, which can then cause neuronal damage and eventually lead to neurodegeneration [63,64].

9. New Pathway of AD—The Infectious Theory

The idea that infectious agents in the brain play a role in the pathogenesis of AD was proposed almost 30 years ago. However, this theory was largely disregarded by the AD research community for many years owing to the lack of substantial evidence. Several recent discoveries have reignited interest in the infectious theory of AD. Researchers represented by Robinson and Bishop have suggested that AD is the result of viral and bacterial infections, such as herpes simplex virus type 1 (HSV-1) [65], Porphyromonas gingivalis [66], and Borrelia burgdorferi [67]. Aβ is an antimicrobial peptide that may aggregate in response to the presence of infectious agents in the brain [68,69,70,71,72]. This hypothesis is supported by various findings such as the identification of microbial DNA in Aβ plaques [73], the stimulation of Aβ production by infectious pathogens [71,74], and the discovery of antimicrobial activity of Aβ [75].
The above hypotheses indicate different aspects of the pathogenesis of AD; however, the exact mechanism is still unclear. Currently, it is generally believed that AD is a disease caused by multiple factors that can work synergistically and form a feedback loop mechanism (Figure 1).

10. Flavonoids

At present, the clinical drug therapy for AD is mainly divided into two categories. One is AChE inhibitors, represented by donepezil, and is suitable for symptomatic relief of mild-to-moderate AD. Another kind is N-methyl-D-aspartate receptor (NMDA) antagonists, represented by memantine, and is suitable for symptomatic relief of severe AD. AChE inhibitors can inhibit the activity of AChE, which leads to an increase in neural ACh levels and improves cognition and memory. NMDA antagonists can inhibit the overactivation of NMDA receptor. The overactivation of NMDA receptors is an important factor leading to cognitive impairment in AD. However, neither class of drugs slowed the progression of AD. They can only improve the quality of life of AD patients. At the same time, these drugs have some side effects, such as lead to vomiting, insomnia and diarrhea, which reduce the compliance of patients with such drugs. Therefore, it is urgent to develop safe and effective pharmacological treatments for AD treatment
Flavonoids are a class of secondary metabolites that have attracted attention from the pharmaceutical industry because of their versatile therapeutic properties. In addition to their medicinal values, flavonoids constitute a part of the human diet due to their abundance in vegetables, fruits, seeds, and beverages (such as coffee, tea, and red wine). More than 9000 different flavonoids have been identified, all of which are divided into six subclasses based on their molecular structure (Figure 2). The basic configuration of flavonoids is C6-C3-C6. Based on the structure of the C ring attached to the A and B rings and the unsaturation of the C ring, flavonoids can be categorized into flavones, flavanones, isoflavones, flavonols or flavan, and anthocyanins, whereas the nonflavonoid group comprises phenolic and lignan acids [76,77]. The structures of flavonoids discussed in this review are summarized in Table 1.
In plants, flavonoids have long been thought to be synthesized in specific parts and are responsible for the color and aroma of flowers. They are used to attract pollinators to aid in seed dispersion, spore germination, and seedling growth and development [78]. Flavonoids play an important role in plants in resisting biological and abiotic stress while acting as ultraviolet filters [79,80]. Moreover, flavonoids have been shown to have a positive impact on human and animal health, and the current interest in these compounds is related to disease therapy and chemoprevention [81]. In both in silico analysis (Table 2) and various models (Table 3), flavonoids have exhibited good biological activities through different pathways, and owing to their antioxidant, anti-inflammatory, anti-amyloid fibrotic, anti-bacterial, enzyme-regulating, and other capabilities, flavonoids have several biochemical and pharmacological effects in the management of AD (Table 3) and other diseases. Corresponding to the pathogenesis hypothesis of AD summarized above, the potential targets for flavonoids to play a role in AD as well as the structure–activity relationship and relevant experimental evidence for each target are summarized below.

11. Flavonoids Exert Anti-AD Effects by Affecting Aβ

Although there are many hypotheses about the pathogenesis of AD, Aβ has always been regarded as the most important substance leading to AD. Currently, the two passive immunizations against Aβ, bapineuzumab and solanezumab, have failed in their phase III clinical trials; nevertheless, there are still many anti-AD studies based on the “amyloid cascade hypothesis”.
Vepsäläinen et al. found that anthocyanin-rich bilberry or blackcurrant extracts can decrease the levels of C-terminal fragment of APP in the cerebral cortex of APP/PS1 mice (APdE9) and reduce behavioral abnormalities associated with AD [140]. It has also been reported that the oral administration of grape-derived polyphenols, composed of catechin and epicatechin in monomeric (~8%), oligomeric (75%), and polymeric forms (~17%), for five months can prevent Aβ oligomerization and attenuate AD-type cognitive impairment in a transgenic mouse model of AD of Tg2576 and APP/PS1 mice [141,142]. A study on the long-term administration of Ginkgo biloba extracts, including flavonols (quercetin, kaempferol, isorhamnetin) and terpenelactone, has also shown that the extracts can considerably decrease the levels of APP in the cortex of Tg2576 mice [143]. Among flavonoids, epigallocatechin gallate (EGCG) from tea is the most widely and thoroughly studied compound. EGCG has been found to reduce Aβ levels in the brain by controlling APP processing [144,145]. Moreover, EGCG can reduce the formation of β-sheet-rich amyloid fibrils by directly binding to the native, unfolded polypeptides [146]. EGCG can also degrade large Aβ fibrils into smaller ones, which are amorphous protein aggregates that are nontoxic [147]. Other classes of flavonoids show anti-amyloidogenic features such as EGCG. In vitro studies show that morin, quercetin, kaempferol, fisetin, chrysin, (+)-catechin, (−)-epicatechin, and myricetin in particular can exert anti-amyloidogenic activity reversibly and specifically by binding to the amyloid fibril structure of Aβ instead of to the monomers of Aβ [148,149,150]. As shown in Table 3, some flavonoids also showed anti-amyloidogenic features by different pathways in AD models. For example, wogonin can attenuate the amyloidogenic pathway by decreasing the levels of β-secretase, APP β-C-terminal fragment, phosphorylated tau, and the extent of Aβ aggregation in a 3xTg-AD mouse model [124].
In summary, flavonoids exert their antiamyloidogenic effects by (1) decreasing the levels of APP; (2) reducing Aβ production by controlling APP processing; (3) protecting against the aggregation of Aβ; and (4) degrading large Aβ fibrils into smaller ones (Figure 3). Three structural characteristics of natural flavonoids have been proposed to explain their inhibitory activity against the aggregation of Aβ in vitro. These structural characteristics include (1) catechol-type flavonoids, which can form Michael adducts with the side chains of Lys16 and Lys28 in monomeric Aβ42 through flavonoid autoxidation, and (2) non-catechol-type flavonoids with planarity due to α,β-unsaturated carbonyl groups that can interact with the intermolecular β-sheet region in Aβ42 aggregates, especially aromatic rings such as those in Phe19 and Phe20 [151].

12. Flavonoids Exhibit Anti-AD Effects through Anti-Inflammatory Activity

Inflammation is one of the main causes of AD despite the fact that neuroinflammation is usually thought to be the result of AD pathogenesis [152]. Flavonoids have been shown to exhibit anti-inflammatory activity in various in vitro and in vivo models [153]. Furthermore, some reports about flavonoids alleviating AD symptoms through anti-inflammatory effects are presented in Table 3. The effects of flavonoid-rich foods on inflammation in humans have also been reported. For example, supplementation with flavanol-rich black tea and cocoa tablets for 4 weeks can increase P-selectin plasma levels [154,155], and the consumption of black tea for 6 weeks may reduce CRP levels [156]. Estruch et al. reported the reduction of the plasma levels of fibrinogen, IL-1α, CRP, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 after 4 weeks of red wine consumption [157]. Carmela Spagnuolo et al. reviewed the role of inflammation in neurodegenerative diseases, highlighting the potential therapeutic effects of flavonoids as anti-inflammation agents [158].
The anti-inflammatory effect of flavonoids can be attributed to the inhibition of the synthesis and activity of different pro-inflammatory mediators such as eicosanoids, cytokines, adhesion molecules, and C-reactive protein.
Firstly, flavonoids can inhibit the synthesis and activity of different pro-inflammatory enzymes, which can include cyclooxygenase-2 (COX-2), lipoxygenase (LOX), and inducible NO synthase (iNOS). COX-2 is an inducible enzyme expressed only after being stimulated by an inflammatory stimulus; it plays a role in prostaglandin synthesis for the induction of inflammation [159]. LOX catalyzes the oxidation of unsaturated fatty acids such as arachidonic acid in white blood cells, which are involved in the inflammatory response [160]. The studies were carried out using in silico methods to explore the binding modes between COX-2 and the commercially available flavonoids, including silibinin, galangin, scopoletin, hesperitin, genistein, daidzein, esculetin, taxifolin, naringenin, and celecoxib, and the findings show that these flavonoids have high binding energy [161]. The structure–activity relationship between flavonoids and COX-2 can be summarized as follows. Flavanones and chalcones do not have an inhibitory effect on the COX-2 protein. In flavones, the olefin at C2 and C3 forms a planar structure that is important for COX-2 inhibition. The presence of 5,7-; 6,7-; and 7,8-dihydroxy groups abolish activity, but COX-2 inhibition is observed if a hydroxy group is present in the B ring, such as in luteolin, where the 3′-OH coordinates with Ser353 and the 4′-OH coordinates with Leu352. Among flavonols, the olefin at C2 and C3 forms a planar structure, which is also an important aspect. The presence of the 5,7-dihydroxy group enhances the COX-2 inhibitory effect, and the substituent moiety at C3′ and C4′ also increases COX-2 inhibition as does the carbonyl group at C4. A B ring capable of rotation is also important for activity; thus, morin is an ineffective inhibitor of the COX-2. For flavone glycosides, glycosyl substitution on C3 has minimal effect on the binding of inhibitors and COX-2. Similarly, in silico docking studies have reported the inhibitory effect of various flavonoids against LOX, and the LOX inhibitory activity of the selected compounds was found to be decreased in the order of morin, azelastine, daidzein, naringenin, esculetin, galangin, scopoletin, taxifolin, silbinin, and genistein [162]. Moreover the structure–activity relationship among a series of flavonoids concerning 5-LOX inhibition was assessed through a systematic study of the inhibition of the formation of LTB4 in human neutrophils, and the results showed that (1) the presence of a hydroxyl group in the flavonoid molecule is not essential; (2) a catechol arrangement reinforces the inhibitory effect; (3) in the presence of a catechol arrangement, the inhibitory potency inversely correlates with the number of hydroxyl groups; and (4) a 2,3-double bond in the C ring strengthens the inhibitory effect [163]. Nitric oxide (NO) produced by iNOS is one of the inflammatory mediators. In lipopolysaccharide (LPS)-treated RAW cells, flavonoids such as apigenin, genistein, and kaempferol have been shown to inhibit NO production by reducing iNOS expression and do not directly inhibit iNOS enzyme activity [164]. The structure–activity relationship of flavonoids with respect to iNOS expression inhibition is as follows. A C-2,3 double bond and 5,7-dihydroxyl groups in the A ring might be important for the inhibitory activity of flavonoids. In addition, the 8-methoxy group in the A ring and the 4′- or 3′,4′-vicinal substitutions in the B ring may favorably affect inhibitory activity, whereas 2′,4′-(meta)-hydroxy substitution in the B ring (morin) abolish inhibitory activity. The 3-hydroxy moiety in the C ring might reduce activity; thus, the inhibition of NO production by flavone derivatives such as chrysin, apigenin, and luteolin is stronger than that achieved using flavonol derivatives such as galangin and quercetin.
Secondly, flavonoids can decrease the expression of different pro-inflammatory cytokines/chemokines including TNF-α, IL-1β, IL-6, IL-8, and monocyte-chemoattractant protein-1 in different cell types such as RAW macrophages, Jurkat T cells, and peripheral blood mononuclear cells. Quercetin and catechins exert a synergistic inhibitory effect on TNF-α and IL-1β to enhance the release of the anti-inflammatory cytokine IL-10 [165]. Genistein has been reported to inhibit IL-1β, IL-6, and TNF-α production in LPS-induced human blood monocytes and RAW cells [166,167]. Silybin and quercetin have been shown to inhibit TNF-α production in LPS-treated RAW cells, and the action of quercetin has been attributed to inhibiting MAPK and AP-1 DNA binding [167,168].

13. Flavonoids Exert Anti-AD Effects through Antioxidant Activity

Oxidative stress is one of the direct causes of AD. Almost every class of flavonoids can function as antioxidants. It has been reported that flavones and catechins may be the most powerful flavonoids that can protect from ROS. Oliveira et al. reviewed the antioxidant effect of flavonoids present in Euterpe oleracea martius and neurodegenerative disease [77], and the same is true of other plant-derived flavonoids.
Flavonoids can prevent injury caused by free radicals in various ways. One way is the direct scavenging of free radicals. Flavonoids can be oxidized by free radicals, causing the radicals to become more stable and less reactive [169], and this occurs due to the high reactivity of the hydroxy groups in flavonoids. Bors et al. [170] summarized the relationship between the structure of flavonoids and their free radical-scavenging activity and reported that the key determinants for radical-scavenging effect are (1) the presence of a catechol group in the B ring, which has better electron-donating properties and is the target of radicals, and (2) a 2,3-double bond conjugated with the 4-oxo group, which is responsible for electron delocalization.
Another antioxidant mechanism of flavonoids is the suppression of ROS formation by inhibiting enzymes or chelating trace elements that are involved in free-radical production, such as xanthine oxidase (XO), free iron, and copper. Several flavonoids such as quercetin, rutin, baicalein, baicalin, and silibin have been found to inhibit XO activity, which leads to decreased oxidative injury [171,172]. Studies on the structure–function relationship by Cos et al. [172] demonstrated that the flavonoid luteolin is the most potent inhibitor of XO. Free metal ions with reducing properties (such as Fe2+ and Cu+) are potential enhancers of reactive oxygen species formation, as exemplified by the reduction of hydrogen peroxide with generation of the highly aggressive hydroxyl radical. On the one hand, flavonoids can chelate these metal ions to remove a causal factor for the development of free radicals. For example, quercetin can prevent oxidative injury in the erythrocyte membrane induced by a number of oxidizing agents that cause the release of iron in its free or redox-active forms [173,174,175]. On the other hand, flavonoids form complexes with metal ions to enhance their antioxidant activity [176]. Morin, kaempferol, and quercetin have been shown to form complexes with Cd(II) and exhibit strong antioxidant activity in vitro [177,178]. Rodríguez-Arce et al. focused on the antioxidant activities of flavonoids and the increase in their antioxidant activity upon coordination with metal ions to generate metal-flavonoid complexes [176]. Furthermore, the metal complexes design may offer an efficient approach for the development of potential new drugs for the treatment of AD. However, flavonoids have also been reported to show prooxidant effects by reducing iron and copper ions. These reduced metals can catalyze the production of hydroxyl radicals through Fenton reaction and lipid radicals through the decomposition of preformed lipid hydroperoxides.
Another antioxidant pathway of flavonoids in vitro is that they can upregulate or enhance antioxidant defense. Several common flavonoids such as quercetin, naringenin, myricetin, and apigenin have been found to enhance antioxidant defense by increasing SOD, CAT, and GPx activities in mice and cell models [179,180,181]. In addition, some flavonoids can also activate the synthesis of low-molecular-weight antioxidants, such as glutathione, or regenerate vitamin E from its radical form.

14. Flavonoids Exert Anti-AD Effects by Acting as Metal-Ion-Chelating Agents

An imbalance of metal ions in the brain can lead to toxicity that is closely related to AD. Several flavonoids have been shown to have excellent ability to chelate metal ions, as described in the section “Flavonoids exert anti-AD effects through antioxidant activity”. In AD, the chelation of metal ions by flavonoids can reduce not only the generation of oxidative stress but also the metal-ion-induced aggregation of Aβ. Initially, myricetin was found to modulate metal-mediated Aβ aggregation and neurotoxicity in vitro and in human neuroblastoma cells owing to its ability to chelate metal and interact with Aβ [182]. Subsequently, (−)-epigallocatechin-3-gallate was found to influence both metal-free and metal-induced Aβ aggregation [183]. DeToma et al. [184] investigated the interaction and reactivity of isoflavone derivatives (aminoisoflavones) with metal-free and metal-associated Aβ and found that the catechol moiety may also be important for the interaction between ligands and metal-associated Aβ.
Mira et al. [185] investigated the interactions and mechanism of flavonoids with iron and copper ions to study their antioxidant activity. In their study, only flavones (apigenin, luteolin, kaempferol, quercetin, myricetin, and rutin) and the flavanol catechin were found to interact with metal ions. The proposed trace metal-binding sites of flavonoids are the catechol moiety in the B ring; the 3-hydroxyl, 4-oxo groups in the heterocyclic ring; and the 4-oxo, 5-hydroxy groups between the heterocyclic ring and the A ring. Among all sites, the catechol moiety is the main site that contributes to metal chelation [183,184]. This is the reason why quercetin can better chelate metal ions than kaempferol. In the study of Mira et al. [186], all flavonoids that were studied were reported to better reduce copper ions than iron ions, and the flavonoids with better Fe3+ reducing activity are those with a 2,3-double bond and possessing both the catechol group in the B ring and the 3-hydroxyl group. The copper-reducing activity seems to depend largely on the number of hydroxyl groups.

15. Flavonoids Exert Anti-AD Effects by Inhibiting AChE

AChE is a key enzyme in the central nervous system. Its inhibition can lead to an increase in neural ACh levels, which is one of the therapeutic targets for symptomatic relief of mild-to-moderate AD [187]. Hence, the inhibition of AChE is one of the central focuses of drug development. Three of the five drugs used in the clinical management of AD in recent years are AChE inhibitors. Several flavonoids have been reported to exert AChE inhibitory effects. Noui et al. [188] explored the bioactive compounds of anticholinesterase activities in Ephedra and found that phenolic including flavonoids showed a potent inhibitory effect against AChE. Khare et al. [189] screened and identified of secondary metabolites to exert AChE inhibitory effects in the bark of Bauhinia variegata by using molecular docking and molecular dynamics simulation and found dihydroquercetin may act as a good inhibitor for treating Alzheimer’s disease. Khan et al. [190] studied the in vitro inhibitory activity of various flavonoids including quercetin, rutin, kaempferol 3-O-β-D-galactoside, and macluraxanthone against AChE. Their results show that quercetin and macluraxanthone possess inhibitory activity against AChE in a concentration-dependent manner. Additionally, macluraxanthone has higher inhibitory activity than quercetin. Myricetin and dihydroxymyricetin have also been shown to effectively inhibit AChE [191,192]. The structural characteristics of dihydroxymyricetin lead to stronger anti-AChE activity than myricetin [191]. Additionally, it has been reported dihydromyricetin improved cognitive impairments in d-galactose-induced AD mice through the inhibition of AChE [193]. In addition to this, Das et al. [194] found that 5,7-dihydroxy-4′-methoxy-8-prenylflavanone isolated from the leaves of Artocarpus anisophyllus Miq. could efficiently inhibit AChE.

16. Flavonoids Exert Anti-AD Effects by Inhibiting Bacteria and Viruses

The infectious theory of AD suggests that bacterial and viral infections can induce AD. In fact, some microorganisms, such as Porphyromonas gingivalis and HSV, have been confirmed to be linked to AD initiation and progression [65,66]. Herbs that are rich in flavonoids have also been used as antimicrobial agents to treat human diseases for centuries. At present, flavonoids have been recognized for antifungal, antiviral, and antibacterial activities. Quercetin, apigenin, and myricetin are three representative flavonoids, all of which have been reported to possess antibacterial activity by acting on multiple targets [195,196]. Quercetin and myricetin have also been shown to have inhibitory activity against P. gingivalis, which is associated with AD [195,196].
Among the antiviral properties of flavonoids, the most studied effect is their anti-HIV property. In vitro studies have shown that several flavonoids can inhibit HIV-1 infection and replication by inhibiting HIV-1 enzymes (HIV-1 reverse transcriptase, HIV-1 integrase, and HIV-1 proteinase). These flavonoids include baicalin, baicalein, myricetin, quercetin, robustaflavone, hinokiflavone, robinetin, and quercetagetin [197,198,199,200]. Flavonoids also have an inhibitory effect on many RNA and DNA viruses such as HSV, respiratory syncytial virus, poliovirus, and Sindbis virus by inhibiting their replication and preventing infectivity [201,202]. Lyu et al. [203] found that flavanols and flavonols potentially have higher anti-HSV activity than flavones. In their study, epicatechin, epicatechin-3-gallate, galangin, and kaempferol showed strong anti-HSV activity, whereas catechin, EGC, EGCG, naringenin, chrysin, baicalin, fisetin, myricetin, quercetin, and genistein showed moderate activity. In those experiments, flavanols and flavonols appeared to be more active than flavones. The anti-P. gingivalis and anti-HSV effects of flavonoids should help reduce the risk of AD.
Taken together, the findings indicate that flavonoids can be potential candidates for the multitarget prevention and treatment of AD. They may help slow the progression of AD or delay its onset. These reports suggest that different flavonoids may exhibit anti-AD activities by targeting different targets. for the same target, flavonoids of different structures have different activity, and a catechol group and in the B ring and a 2,3-double bond in the C ring may be important for various activities of flavonoids. Thus, simultaneously using multiple flavonoids or dietary flavonoid supplements may be an effective multitarget approach for the prevention and treatment of AD. However, because some reports present different results for the same flavonoid, it is clear that more experiments and/or clinical trials are needed to confirm the anti-AD effect of flavonoids.

17. Conclusions

The pathogenesis of AD involves several mechanisms and factors, including the “amyloid cascade hypothesis”, “tau hypothesis”, “oxidative stress hypothesis”, and “inflammation hypothesis”. Growing knowledge of AD has indicated that these factors work synergistically, forming a feedback loop mechanism that leads to the development of AD. In addition, pathophysiological brain alterations usually occur decades before the clinical signs and symptoms manifest. Consequently, the current treatment strategies for AD should be multitargeted and used for early intervention to jointly prevent disease progression.
Flavonoids are ideal compounds and are in line with the treatment strategies for AD for multiple reasons. First, flavonoids have a wide range of activities that could make them particularly effective for blocking AD-associated pathogenic factors. Second, flavonoids, especially flavonoid glycosides, can cross the blood–brain barrier and directly act on the brain. Third, flavonoids can be isolated from various plants and effectively used to reduce the incidence of age-related diseases, as indicated by studies using diverse animal- and cell-based models. Collectively, flavonoids can be regarded as prophylactics to slow the advancement or to avert the onset of AD. Consuming foods rich in flavonoids, such as by following a Mediterranean diet, is recommended, especially for the elderly. Flavonoids can also be promising candidates as anti-AD drugs.
However, the therapeutic development of flavonoids has been hindered by an ongoing lack of clear mechanistic data that fully consider metabolism and the bioavailability of flavonoids in vivo. There is also a lack of translational research and clinical evidence of these promising compounds. Therefore, further studies are required to address the specific processes by which flavonoids exhibit their neuroprotective effects and to determine the role of flavonoids in humans.

Author Contributions

J.L., C.L. and X.C., conceptualization, investigation, and writing—original draft preparation; C.L., M.S. and X.C., writing—review and editing; J.L., M.S. and X.C., visualization, supervision, and funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Science and Technology Innovation Program for Colleges and Universities of Shanxi Province, Department of Education of Shanxi Province, China (Grant No. 2019L0055).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Barnes, D.E.; Yaffe, K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011, 10, 819–828. [Google Scholar] [CrossRef]
  2. Jia, J.; Wei, C.; Chen, S.; Li, F.; Tang, Y.; Qin, W.; Zhao, L.; Jin, H.; Xu, H.; Wang, F.; et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimer’s Dement. J. Alzheimer’s Assoc. 2018, 14, 483–491. [Google Scholar] [CrossRef] [PubMed]
  3. Morris, M.C.; Tangney, C.C.; Wang, Y.; Sacks, F.M.; Bennett, D.A.; Aggarwal, N.T. MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimer’s Dement. J. Alzheimer’s Assoc. 2015, 11, 1007–1014. [Google Scholar] [CrossRef]
  4. Beking, K.; Vieira, A. Flavonoid intake and disability-adjusted life years due to Alzheimer’s and related dementias: A population-based study involving twenty-three developed countries. Public Health Nutr. 2010, 13, 1403–1409. [Google Scholar] [CrossRef] [PubMed]
  5. Commenges, D.; Scotet, V.; Renaud, S.; Jacqmin-Gadda, H.; Barberger-Gateau, P.; Dartigues, J.-F. Intake of flavonoids and risk of dementia. Eur. J. Epidemiol. 2000, 16, 357–363. [Google Scholar] [CrossRef]
  6. de Andrade Teles, R.B.; Diniz, T.C.; Costa Pinto, T.C.; de Oliveira Junior, R.G.; Gama, E.S.M.; de Lavor, E.M.; Fernandes, A.W.C.; de Oliveira, A.P.; de Almeida Ribeiro, F.P.R.; da Silva, A.A.M.; et al. Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences. Oxid. Med. Cell. Longev. 2018, 2018, 7043213. [Google Scholar] [CrossRef]
  7. Hole, K.L.; Williams, R.J. Flavonoids as an Intervention for Alzheimer’s Disease: Progress and Hurdles Towards Defining a Mechanism of Action. Brain Plast. 2021, 6, 167–192. [Google Scholar] [CrossRef]
  8. Uddin, S.; Kabir, T.; Niaz, K.; Jeandet, P.; Clément, C.; Mathew, B.; Rauf, A.; Rengasamy, K.R.; Sobarzo-Sánchez, E.; Ashraf, G.; et al. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer’s Disease. Molecules 2020, 25, 1267. [Google Scholar] [CrossRef]
  9. Xia, H. Extensive metabolism of flavonoids relevant to their potential efficacy on Alzheimer’s disease. Drug Metab. Rev. 2021, 53, 563–591. [Google Scholar] [CrossRef]
  10. Pervin, M.; Unno, K.; Ohishi, T.; Tanabe, H.; Miyoshi, N.; Nakamura, Y. Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases. Molecules 2018, 23, 1297. [Google Scholar] [CrossRef] [Green Version]
  11. Khan, H.; Ullah, H.; Aschner, M.; Cheang, W.S.; Akkol, E.K. Neuroprotective Effects of Quercetin in Alzheimer’s Disease. Biomolecules 2019, 10, 59. [Google Scholar] [CrossRef] [PubMed]
  12. Salehi, B.; Venditti, A.; Sharifi-Rad, M.; Kręgiel, D.; Sharifi-Rad, J.; Durazzo, A.; Lucarini, M.; Santini, A.; Souto, E.B.; Novellino, E.; et al. The Therapeutic Potential of Apigenin. Int. J. Mol. Sci. 2019, 20, 1305. [Google Scholar] [CrossRef]
  13. Nakajima, A.; Ohizumi, Y. Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer’s Disease and Parkinson’s Disease. Int. J. Mol. Sci. 2019, 20, 3380. [Google Scholar] [CrossRef] [PubMed]
  14. Ravula, A.R.; Teegala, S.B.; Kalakotla, S.; Pasangulapati, J.P.; Perumal, V.; Boyina, H.K. Fisetin, potential flavonoid with multifarious targets for treating neurological disorders: An updated review. Eur. J. Pharmacol. 2021, 910, 174492. [Google Scholar] [CrossRef] [PubMed]
  15. Mishra, A.; Mishra, P.S.; Bandopadhyay, R.; Khurana, N.; Angelopoulou, E.; Paudel, Y.N.; Piperi, C. Neuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders. Molecules 2021, 26, 6456. [Google Scholar] [CrossRef] [PubMed]
  16. Bondi, M.W.; Edmonds, E.C.; Salmon, D.P. Alzheimer’s disease: Past, present, and future. J. Int. Neuropsychol. Soc. 2017, 23, 818–831. [Google Scholar] [CrossRef]
  17. O’Brien, C. Science History: Auguste D. and Alzheimer’s Disease. Science 1996, 273, 28. [Google Scholar] [CrossRef]
  18. Hardy, J.A.; Higgins, G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992, 256, 184–185. [Google Scholar] [CrossRef]
  19. De Strooper, B. Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process. Physiol. Rev. 2010, 90, 465–494. [Google Scholar] [CrossRef]
  20. Murphy, M.P.; LeVine, H., III. Alzheimer’s Disease and the Amyloid-β Peptide. J. Alzheimer’s Dis. 2010, 19, 311–323. [Google Scholar] [CrossRef] [Green Version]
  21. Sambamurti, K.; Greig, N.H.; Lahiri, D.K. Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer ‘s Disease. NeuroMolecular Med. 2002, 1, 1–32. [Google Scholar] [CrossRef]
  22. De Felice, F.G.; Ferreira, S.T. β-Amyloid Production, Aggregation, and Clearance as Targets for Therapy in Alzheimer’s Disease. Cell. Mol. Neurobiol. 2002, 22, 545–563. [Google Scholar] [CrossRef] [PubMed]
  23. Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2011, 1, a006189. [Google Scholar] [CrossRef] [PubMed]
  24. Struble, R.G.; Ala, T.; Patrylo, P.R.; Brewer, G.J.; Yan, X.-X. Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer’s Type? J. Alzheimer’s Dis. 2010, 22, 393–399. [Google Scholar] [CrossRef] [PubMed]
  25. Varnum, M.M.; Ikezu, T. The Classification of Microglial Activation Phenotypes on Neurodegeneration and Regeneration in Alzheimer’s Disease Brain. Arch. Immunol. Et Ther. Exp. 2012, 60, 251–266. [Google Scholar] [CrossRef]
  26. Selkoe, D.J. Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies. Ann. Intern. Med. 2004, 140, 627–638. [Google Scholar] [CrossRef]
  27. Soria-Lopez, J.A.; González, H.M.; Léger, G.C. Alzheimer’s disease. In Handbook of Clinical Neurology, 3rd ed.; DeKosky, S.T., Asthana, S., Eds.; Elsevier: Boston, MA, USA, 2019; Volume 167, pp. 231–255. [Google Scholar] [CrossRef]
  28. Naseri, N.N.; Wang, H.; Guo, J.; Sharma, M.; Luo, W. The complexity of tau in Alzheimer’s disease. Neurosci. Lett. 2019, 705, 183–194. [Google Scholar] [CrossRef]
  29. Pirscoveanu, D.F.V.; Pirici, I.; Tudorica, V.; Balseanu, T.A.; Albu, V.C.; Bondari, S.; Bumbea, A.M.; Pirscoveanu, M. Tau protein in neurodegenerative diseases–A review. Rom. J. Morphol. Embryol. 2017, 58, 1141–1150. [Google Scholar]
  30. Bejanin, A.; Schonhaut, D.; La Joie, R.; Kramer, J.H.; Baker, S.L.; Sosa, N.; Ayakta, N.; Cantwell, A.; Janabi, M.; Lauriola, M.; et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain 2017, 140, 3286–3300. [Google Scholar] [CrossRef]
  31. Pratico, M. Evidence of Oxidative Stress in Alzheimer’s Disease Brain and Antioxidant Therapy. Ann. New York Acad. Sci. 2008, 1147, 70–78. [Google Scholar] [CrossRef]
  32. Sokoloff, L. Energetics of Functional Activation in Neural Tissues. Neurochem. Res. 1999, 24, 321–329. [Google Scholar] [CrossRef]
  33. Pocernich, C.B.; Butterfield, D.A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim. et Biophys. Acta (BBA)-Mol. Basis Dis. 2012, 1822, 625–630. [Google Scholar] [CrossRef] [PubMed]
  34. Nunomura, A.; Castellani, R.J.; Zhu, X.; Moreira, P.I.; Perry, G.; Smith, M.A. Involvement of Oxidative Stress in Alzheimer Disease. J. Neuropathol. Exp. Neurol. 2006, 65, 631–641. [Google Scholar] [CrossRef]
  35. Chen, Z.; Zhong, C. Oxidative stress in Alzheimer’s disease. Neurosci. Bull. 2014, 30, 271–281. [Google Scholar] [CrossRef] [PubMed]
  36. Johnstone, M.; Gearing, A.J.; Miller, K.M. A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced. J. Neuroimmunol. 1999, 93, 182–193. [Google Scholar] [CrossRef]
  37. Butterfield, D.A.; Reed, T.; Newman, S.F.; Sultana, R. Roles of Amyloid β-Peptide-Associated Oxidative Stress and Brain Protein Modifications in the Pathogenesis of Alzheimer’s Disease and Mild Cognitive Impairment. Free Radic. Biol. Med. 2007, 43, 658–677. [Google Scholar] [CrossRef]
  38. Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018, 14, 450–464. [Google Scholar] [CrossRef]
  39. Scrivo, R.; Vasile, M.; Bartosiewicz, I.; Valesini, G. Inflammation as “common soil” of the multifactorial diseases. Autoimmun. Rev. 2011, 10, 369–374. [Google Scholar] [CrossRef]
  40. Zhang, B.; Gaiteri, C.; Bodea, L.-G.; Wang, Z.; McElwee, J.; Podtelezhnikov, A.A.; Zhang, C.; Xie, T.; Tran, L.; Dobrin, R.; et al. Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease. Cell 2013, 153, 707–720. [Google Scholar] [CrossRef]
  41. Song, W.; Hooli, B.; Mullin, K.; Jin, S.C.; Cella, M.; Ulland, T.K.; Wang, Y.; Tanzi, R.E.; Colonna, M. Alzheimer’s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimer’s Dement. J. Alzheimer’s Assoc. 2017, 13, 381–387. [Google Scholar] [CrossRef] [Green Version]
  42. Bolos, M.; Perea, J.R.; Avila, J. Alzheimer’s disease as an inflammatory disease. Biomol. Concepts 2017, 8, 37–43. [Google Scholar] [CrossRef] [PubMed]
  43. Fillit, H.; Ding, W.; Buee, L.; Kalman, J.; Altstiel, L.; Lawlor, B.; Wolf-Klein, G. Elevated circulating tumor necrosis factor levels in Alzheimer’s disease. Neurosci. Lett. 1991, 129, 318–320. [Google Scholar] [CrossRef]
  44. Bauer, J.; Strauss, S.; Schreiter-Gasser, U.; Ganter, U.; Schlegel, P.; Witt, I.; Yolk, B.; Berger, M. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett. 1991, 285, 111–114. [Google Scholar] [CrossRef]
  45. Stamouli, E.; Politis, A. Pro-inflammatory cytokines in Alzheimer’s disease. Psychiatriki 2016, 27, 264–275. [Google Scholar] [CrossRef]
  46. Taipa, R.; das Neves, S.P.; Sousa, A.L.; Fernandes, J.; Pinto, C.; Correia, A.P.; Santos, E.; Pinto, P.S.; Carneiro, P.; Costa, P.; et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer’s disease and their correlation with cognitive decline. Neurobiol. Aging 2019, 76, 125–132. [Google Scholar] [CrossRef]
  47. Onyango, I.; Jauregui, G.; Čarná, M.; Bennett, J.; Stokin, G. Neuroinflammation in Alzheimer’s Disease. Biomedicines 2021, 9, 524. [Google Scholar] [CrossRef]
  48. Sastre, M.; Klockgether, T.; Heneka, M.T. Contribution of inflammatory processes to Alzheimer’s disease: Molecular mechanisms. Int. J. Dev. Neurosci. 2006, 24, 167–176. [Google Scholar] [CrossRef]
  49. Casal, C.; Serratosa, J.; Tusell, J.M. Effects of β-AP peptides on activation of the transcription factor NF-κB and in cell proliferation in glial cell cultures. Neurosci. Res. 2004, 48, 315–323. [Google Scholar] [CrossRef]
  50. Sastre, M.; Dewachter, I.; Landreth, G.E.; Willson, T.M.; Klockgether, T.; Van Leuven, F.; Heneka, M.T. Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase. J. Neurosci. 2003, 23, 9796–9804. [Google Scholar] [CrossRef]
  51. Chen, C.-H.; Zhou, W.; Liu, S.; Deng, Y.; Cai, F.; Tone, M.; Tone, Y.; Tong, Y.; Song, W. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int. J. Neuropsychopharmacol. 2011, 15, 77–90. [Google Scholar] [CrossRef] [Green Version]
  52. Guo, J.-T.; Yu, J.; Grass, D.; De Beer, F.C.; Kindy, M.S. Inflammation-Dependent Cerebral Deposition of Serum Amyloid A Protein in a Mouse Model of Amyloidosis. J. Neurosci. 2002, 22, 5900–5909. [Google Scholar] [CrossRef] [PubMed]
  53. Yoo, J.H.; Valdovinos, M.G.; Williams, D.C. Relevance of Donepezil in Enhancing Learning and Memory in Special Populations: A Review of the Literature. J. Autism Dev. Disord. 2007, 37, 1883–1901. [Google Scholar] [CrossRef] [PubMed]
  54. Hasselmo, M.E.; Anderson, B.P.; Bower, J.M. Cholinergic modulation of cortical associative memory function. J. Neurophysiol. 1992, 67, 1230–1246. [Google Scholar] [CrossRef] [PubMed]
  55. Sarter, M.; Bruno, J.P. Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis. Brain Res. Rev. 1997, 23, 28–46. [Google Scholar] [CrossRef]
  56. Brinkman, S.D.; Gershon, S. Measurement of cholinergic drug effects on memory in alzheimer’s disease. Neurobiol. Aging 1983, 4, 139–145. [Google Scholar] [CrossRef]
  57. Summers, W.K.; Majovski, L.V.; Marsh, G.M.; Tachiki, K.; Kling, A. Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type. N Engl. J. Med. 1986, 315, 1241–1245. [Google Scholar] [CrossRef] [PubMed]
  58. Sharma, K. Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). Mol. Med. Rep. 2019, 20, 1479–1487. [Google Scholar] [CrossRef]
  59. Saxena, M.; Dubey, R. Target Enzyme in Alzheimer’s Disease: Acetylcholinesterase Inhibitors. Curr. Top. Med. Chem. 2019, 19, 264–275. [Google Scholar] [CrossRef]
  60. Akıncıoğlu, H.; Gulcin, I. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer’s Disease. Mini-Rev. Med. Chem. 2020, 20, 703–715. [Google Scholar] [CrossRef]
  61. Lovell, M.; Robertson, J.; Teesdale, W.; Campbell, J.; Markesbery, W. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci. 1998, 158, 47–52. [Google Scholar] [CrossRef]
  62. James, S.A.; Churches, Q.I.; de Jonge, M.D.; Birchall, I.E.; Streltsov, V.; McColl, G.; Adlard, P.A.; Hare, D.J. Iron, Copper, and Zinc Concentration in Aβ Plaques in the APP/PS1 Mouse Model of Alzheimer’s Disease Correlates with Metal Levels in the Surrounding Neuropil. ACS Chem. Neurosci. 2016, 8, 629–637. [Google Scholar] [CrossRef] [PubMed]
  63. Valko, M.; Jomova, K.; Rhodes, C.J.; Kuča, K.; Musílek, K. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease. Arch. Toxicol. 2016, 90, 1–37. [Google Scholar] [CrossRef] [PubMed]
  64. Liu, Y.; Nguyen, M.; Robert, A.; Meunier, B. Metal Ions in Alzheimer’s Disease: A Key Role or Not? Accounts Chem. Res. 2019, 52, 2026–2035. [Google Scholar] [CrossRef] [PubMed]
  65. Bearer, E.L.; Wu, C. Herpes Simplex Virus, Alzheimer’s Disease and a Possible Role for Rab GTPases. Front. Cell Dev. Biol. 2019, 7, 134. [Google Scholar] [CrossRef]
  66. Dominy, S.S.; Lynch, C.; Ermini, F.; Benedyk, M.; Marczyk, A.; Konradi, A.; Nguyen, M.; Haditsch, U.; Raha, D.; Griffin, C.; et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 2019, 5, eaau3333. [Google Scholar] [CrossRef]
  67. Miklossy, J.; Khalili, K.; Gern, L.; Ericson, R.L.; Darekar, P.; Bolle, L.; Hurlimann, J.; Paster, B.J. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J. Alzheimer’s Dis. 2005, 6, 639–649; discussion 673–681. [Google Scholar] [CrossRef]
  68. Bishop, G.M.; Robinson, S.R. The amyloid hypothesis: Let sleeping dogmas lie? Neurobiol. Aging 2002, 23, 1101–1105. [Google Scholar] [CrossRef]
  69. Robinson, S.R.; Bishop, G.M. Aβ as a bioflocculant: Implications for the amyloid hypothesis of Alzheimer’s disease. Neurobiol. Aging 2002, 23, 1051–1072. [Google Scholar] [CrossRef]
  70. Wozniak, M.A.; Mee, A.P.; Itzhaki, R.F. Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J. Pathol. 2009, 217, 131–138. [Google Scholar] [CrossRef]
  71. Santana, S.; Recuero, M.; Bullido, M.J.; Valdivieso, F.; Aldudo, J. Herpes simplex virus type I induces the accumulation of intracellular β-amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells. Neurobiol. Aging 2012, 33, 430.e19–430.e33. [Google Scholar] [CrossRef]
  72. Miklossy, J. Bacterial Amyloid and DNA are Important Constituents of Senile Plaques: Further Evidence of the Spirochetal and Biofilm Nature of Senile Plaques. J. Alzheimer’s Dis. 2016, 53, 1459–1473. [Google Scholar] [CrossRef] [PubMed]
  73. Krut, J.J.; Zetterberg, H.; Blennow, K.; Cinque, P.; Hagberg, L.; Price, R.W.; Studahl, M.; Gisslén, M. Cerebrospinal fluid Alzheimer’s biomarker profiles in CNS infections. J. Neurol. 2012, 260, 620–626. [Google Scholar] [CrossRef] [PubMed]
  74. De Chiara, G.; Marcocci, M.E.; Civitelli, L.; Argnani, R.; Piacentini, R.; Ripoli, C.; Manservigi, R.; Grassi, C.; Garaci, E.; Palamara, A.T. APP Processing Induced by Herpes Simplex Virus Type 1 (HSV-1) Yields Several APP Fragments in Human and Rat Neuronal Cells. PLoS ONE 2010, 5, e13989. [Google Scholar] [CrossRef] [PubMed]
  75. Bourgade, K.; Le Page, A.; Bocti, C.; Witkowski, J.M.; Dupuis, G.; Frost, E.H.; Fülöp, T., Jr. Protective Effect of Amyloid-β Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model. J. Alzheimer’s Dis. 2016, 50, 1227–1241. [Google Scholar] [CrossRef]
  76. Panche, A.N.; Diwan, A.D.; Chandra, S.R. Flavonoids: An overview. J. Nutr. Sci. 2016, 5, e47. [Google Scholar] [CrossRef]
  77. De Oliveira, N.K.S.; Almeida, M.R.S.; Pontes, F.M.M.; Barcelos, M.P.; Silva, C.H.T.D.P.D.; Rosa, J.M.C.; Cruz, R.A.S.; Hage-Melim, L.I.D.S. Antioxidant Effect of Flavonoids Present in Euterpe oleracea Martius and Neurodegenerative Diseases: A Literature Review. Central Nerv. Syst. Agents Med. Chem. 2019, 19, 75–99. [Google Scholar] [CrossRef]
  78. Grotewold, E. The genetics and biochemistry of floral pigments. Annu. Rev. Plant Biol. 2006, 57, 761–780. [Google Scholar] [CrossRef]
  79. Takahashi, A.; Ohnishi, T. The Significance of the Study about the Biological Effects of Solar Ultraviolet Radiation using the Exposed Facility on the International Space Station. Biol. Sci. Space 2004, 18, 255–260. [Google Scholar] [CrossRef]
  80. Samanta, A.; Das, G.; Das, S.K. Roles of Flavonoids in Plants. Int. J. Pharm. Sci. Tech. 2011, 6, 11–35. [Google Scholar]
  81. Dixon, R.A.; Pasinetti, G. Flavonoids and Isoflavonoids: From Plant Biology to Agriculture and Neuroscience. Plant Physiol. 2010, 154, 453–457. [Google Scholar] [CrossRef]
  82. Ali, B.; Jamal, Q.M.; Shams, S.; Al-Wabel, N.A.; Siddiqui, M.U.; Alzohairy, M.A.; Al Karaawi, M.A.; Kesari, K.K.; Mushtaq, G.; Kamal, M.A. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer’s Disease Treatment. CNS Neurol. Disord.-Drug Targets 2016, 15, 624–628. [Google Scholar] [CrossRef] [PubMed]
  83. Mazumder, M.K.; Choudhury, S. Tea polyphenols as multi-target therapeutics for Alzheimer’s disease: An in silico study. Med Hypotheses 2019, 125, 94–99. [Google Scholar] [CrossRef] [PubMed]
  84. Razzaghi-Asl, N.; Karimi, A.; Ebadi, A. The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor. Comput. Biol. Chem. 2018, 77, 307–317. [Google Scholar] [CrossRef] [PubMed]
  85. Bano, S.; Rasheed, M.A.; Jamil, F.; Ibrahim, M.; Kanwal, S. In Silico Identification of Novel Apolipoprotein E4 Inhibitor for Alzheimer’s Disease Therapy. Curr. Comput. Aided-Drug Des. 2019, 15, 97–103. [Google Scholar] [CrossRef] [PubMed]
  86. Sun, Y.-W.; Wang, Y.; Guo, Z.-F.; Du, K.-C.; Meng, D.-L. Systems Pharmacological Approach to Investigate the Mechanism of Ohwia caudata for Application to Alzheimer’s Disease. Molecules 2019, 24, 1499. [Google Scholar] [CrossRef]
  87. Lee, S.; Youn, K.; Lim, G.; Lee, J.; Jun, M. In Silico Docking and In Vitro Approaches towards BACE1 and Cholinesterases Inhibitory Effect of Citrus Flavanones. Molecules 2018, 23, 1509. [Google Scholar] [CrossRef]
  88. Adewole, K.E.; Gyebi, G.A.; Ibrahim, I.M. Amyloid β fibrils disruption by kolaviron: Molecular docking and extended molecular dynamics simulation studies. Comput. Biol. Chem. 2021, 94, 107557. [Google Scholar] [CrossRef]
  89. Gupta, M.K.; Vadde, R. In silico identification of natural product inhibitors for γ-secretase activating protein, a therapeutic target for Alzheimer’s disease. J. Cell. Biochem. 2019, 120, 10323–10336. [Google Scholar] [CrossRef]
  90. Youn, K.; Jun, M. Biological Evaluation and Docking Analysis of Potent BACE1 Inhibitors from Boesenbergia rotunda. Nutrients 2019, 11, 662. [Google Scholar] [CrossRef]
  91. Duan, S.; Guan, X.; Lin, R.; Liu, X.; Yan, Y.; Lin, R.; Zhang, T.; Chen, X.; Huang, J.; Sun, X.; et al. Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: A dual-target drug for the treatment of Alzheimer’s disease. Neurobiol. Aging 2015, 36, 1792–1807. [Google Scholar] [CrossRef]
  92. Rehman, K.; Chohan, T.A.; Waheed, I.; Gilani, Z.; Akash, M.S.H. Taxifolin prevents postprandial hyperglycemia by regulating the activity of α-amylase: Evidence from an in vivo and in silico studies. J. Cell. Biochem. 2019, 120, 425–438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Shimmyo, Y.; Kihara, T.; Akaike, A.; Niidome, T.; Sugimoto, H. Flavonols and flavones as BACE-1 inhibitors: Structure–activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim. et Biophys. Acta (BBA)-Gen. Subj. 2008, 1780, 819–825. [Google Scholar] [CrossRef]
  94. Espargaró, A.; Ginex, T.; Vadell, M.D.M.; Busquets, M.A.; Estelrich, J.; Muñoz-Torrero, D.; Luque, F.J.; Sabate, R. Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs. J. Nat. Prod. 2017, 80, 278–289. [Google Scholar] [CrossRef] [PubMed]
  95. Han, J.; Ji, Y.; Youn, K.; Lim, G.; Lee, J.; Kim, D.H.; Jun, M. Baicalein as a Potential Inhibitor against BACE1 and AChE: Mechanistic Comprehension through In Vitro and Computational Approaches. Nutrients 2019, 11, 2694. [Google Scholar] [CrossRef] [PubMed]
  96. Malar, D.S.; Shafreen, R.B.; Pandian, S.K.; Devi, K.P. Cholinesterase inhibitory, anti-amyloidogenic and neuroprotective effect of the medicinal plant Grewia tiliaefolia–An in vitro and in silico study. Pharm. Biol. 2017, 55, 381–393. [Google Scholar] [CrossRef] [PubMed]
  97. Pan, H.; Zhang, J.; Wang, Y.; Cui, K.; Cao, Y.; Wang, L.; Wu, Y. Linarin improves the dyskinesia recovery in Alzheimer’s disease zebrafish by inhibiting the acetylcholinesterase activity. Life Sci. 2019, 222, 112–116. [Google Scholar] [CrossRef]
  98. Atalar, M.N.; Aras, A.; Türkan, F.; Barlak, N.; Yildiko, Ü.; Karatas, O.F.; Alma, M.H. The effects of Daucus carota extract against PC3, PNT1a prostate cells, acetylcholinesterase, glutathione S-transferase, and α-glycosidase; an in vitro–in silico study. J. Food Biochem. 2021, 45, e13975. [Google Scholar] [CrossRef] [PubMed]
  99. El-Hawary, S.S.; Sayed, A.M.; Issa, M.Y.; Ebrahim, H.S.; Alaaeldin, R.; Elrehany, M.A.; El-Kadder, E.M.A.; Abdelmohsen, U.R. Anti-Alzheimer chemical constituents of Morus macroura Miq.: Chemical profiling, in silico and in vitro investigations. Food Funct. 2021, 12, 8078–8089. [Google Scholar] [CrossRef]
  100. Singh, S.K.; Gaur, R.; Kumar, A.; Fatima, R.; Mishra, L.; Srikrishna, S. The Flavonoid Derivative 2-(4′ Benzyloxyphenyl)-3-hydroxy-chromen-4-one Protects Against Aβ42-Induced Neurodegeneration in Transgenic Drosophila: Insights from In Silico and In Vivo Studies. Neurotox. Res. 2014, 26, 331–350. [Google Scholar] [CrossRef]
  101. Cui, Z.; Sheng, Z.; Yan, X.; Cao, Z.; Tang, K. In Silico Insight into Potential Anti-Alzheimer’s Disease Mechanisms of Icariin. Int. J. Mol. Sci. 2016, 17, 113. [Google Scholar] [CrossRef]
  102. Lemkul, J.A.; Bevan, D.R. Destabilizing Alzheimer’s Aβ42 Protofibrils with Morin: Mechanistic Insights from Molecular Dynamics Simulations. Biochemistry 2010, 49, 3935–3946. [Google Scholar] [CrossRef] [PubMed]
  103. Islam, R.; Zaman, A.; Jahan, I.; Chakravorty, R.; Chakraborty, S. In silico QSAR analysis of quercetin reveals its potential as therapeutic drug for Alzheimer’s disease. J. Young-Pharm. 2013, 5, 173–179. [Google Scholar] [CrossRef] [PubMed]
  104. Katalinić, M.; Rusak, G.; Barović, J.D.; Šinko, G.; Jelić, D.; Antolović, R.; Kovarik, Z. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur. J. Med. Chem. 2010, 45, 186–192. [Google Scholar] [CrossRef]
  105. Youn, K.; Park, J.-H.; Lee, S.; Lee, S.; Lee, J.; Yun, E.-Y.; Jeong, W.-S.; Jun, M. BACE1 Inhibition by Genistein: Biological Evaluation, Kinetic Analysis, and Molecular Docking Simulation. J. Med. Food 2018, 21, 416–420. [Google Scholar] [CrossRef] [PubMed]
  106. Castillo, W.O.; Palomino, N.V.; Takahashi, C.S.; Giuliatti, S. Genistein and Galantamine Combinations Decrease β-Amyloid Peptide (1–42)–Induced Genotoxicity and Cell Death in SH-SY5Y Cell Line: An In Vitro and In Silico Approach for Mimic of Alzheimer’s Disease. Neurotox. Res. 2020, 38, 691–706. [Google Scholar] [CrossRef] [PubMed]
  107. Liu, S.; Cao, X.-L.; Liu, G.-Q.; Zhou, T.; Yang, X.-L.; Ma, B.-X. The in silico and in vivo evaluation of puerarin against Alzheimer’s disease. Food Funct. 2019, 10, 799–813. [Google Scholar] [CrossRef]
  108. Liu, S.; Zhou, T.; Chen, D.; Liu, R.; Qin, H.-H.; Min, Z.-L.; Liu, G.-Q.; Cao, X.-L. In silico-determined compound from the root of Pueraria lobate alleviates synaptic plasticity injury induced by Alzheimer’s disease via the p38MAPK-CREB signaling pathway. Food Funct. 2021, 12, 1039–1050. [Google Scholar] [CrossRef]
  109. Sachdeva, A.K.; Kuhad, A.; Chopra, K. Naringin ameliorates memory deficits in experimental paradigm of Alzheimer’s disease by attenuating mitochondrial dysfunction. Pharmacol. Biochem. Behav. 2014, 127, 101–110. [Google Scholar] [CrossRef]
  110. Meng, X.; Fu, M.; Wang, S.; Chen, W.; Wang, J.; Zhang, N. Naringin ameliorates memory deficits and exerts neuroprotective effects in a mouse model of Alzheimer’s disease by regulating multiple metabolic pathways. Mol. Med. Rep. 2021, 23, 1–13. [Google Scholar] [CrossRef]
  111. Ikram, M.; Muhammad, T.; Rehman, S.U.; Khan, A.; Jo, M.G.; Ali, T.; Kim, M.O. Hesperetin Confers Neuroprotection by Regulating Nrf2/TLR4/NF-κB Signaling in an Aβ Mouse Model. Mol. Neurobiol. 2019, 56, 6293–6309. [Google Scholar] [CrossRef]
  112. He, P.; Yan, S.; Zheng, J.; Gao, Y.; Zhang, S.; Liu, Z.; Liu, X.; Xiao, C. Eriodictyol Attenuates LPS-Induced Neuroinflammation, Amyloidogenesis, and Cognitive Impairments via the Inhibition of NF-κB in Male C57BL/6J Mice and BV2 Microglial Cells. J. Agric. Food Chem. 2018, 66, 10205–10214. [Google Scholar] [CrossRef] [PubMed]
  113. Nan, S.; Wang, P.; Zhang, Y.; Fan, J. Epigallocatechin-3-Gallate Provides Protection Against Alzheimer’s Disease-Induced Learning and Memory Impairments in Rats. Drug Des. Dev. Ther. 2021, ume 15, 2013–2024. [Google Scholar] [CrossRef]
  114. Chen, T.; Yang, Y.; Zhu, S.; Lu, Y.; Zhu, L.; Wang, Y.; Wang, X. Inhibition of Aβ aggregates in Alzheimer’s disease by epigallocatechin and epicatechin-3-gallate from green tea. Bioorg. Chem. 2020, 105, 104382. [Google Scholar] [CrossRef] [PubMed]
  115. Cox, C.J.; Choudhry, F.; Peacey, E.; Perkinton, M.S.; Richardson, J.C.; Howlett, D.R.; Lichtenthaler, S.F.; Francis, P.T.; Williams, R.J. Dietary (−)-epicatechin as a potent inhibitor of βγ-secretase amyloid precursor protein processing. Neurobiol. Aging 2015, 36, 178–187. [Google Scholar] [CrossRef] [PubMed]
  116. Hole, K.L.; Staniaszek, L.E.; Balan, G.M.; Mason, J.M.; Brown, J.T.; Williams, R.J. Oral (−)-Epicatechin Inhibits Progressive Tau Pathology in rTg4510 Mice Independent of Direct Actions at GSK3β. Front. Neurosci. 2021, 15, 697319. [Google Scholar] [CrossRef]
  117. Lim, H.J.; Shim, S.B.; Jee, S.W.; Lee, S.H.; Lim, C.J.; Hong, J.T.; Sheen, Y.Y.; Hwang, D.Y. Green tea catechin leads to global improvement among Alzheimer’s disease-related phenotypes in NSE/hAPP-C105 Tg mice. J. Nutr. Biochem. 2013, 24, 1302–1313. [Google Scholar] [CrossRef]
  118. Ali, F.; Rahul; Jyoti, S.; Naz, F.; Ashafaq, M.; Shahid, M.; Siddique, Y.H. Therapeutic potential of luteolin in transgenic Drosophila model of Alzheimer’s disease. Neurosci. Lett. 2019, 692, 90–99. [Google Scholar] [CrossRef]
  119. Nakajima, A.; Aoyama, Y.; Shin, E.-J.; Nam, Y.; Kim, H.-C.; Nagai, T.; Yokosuka, A.; Mimaki, Y.; Yokoi, T.; Ohizumi, Y.; et al. Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of Alzheimer’s disease (3XTg-AD). Behav. Brain Res. 2015, 289, 69–77. [Google Scholar] [CrossRef]
  120. Kimura, J.; Shimizu, K.; Kajima, K.; Yokosuka, A.; Mimaki, Y.; Oku, N.; Ohizumi, Y. Nobiletin Reduces Intracellular and Extracellular β-Amyloid in iPS Cell-Derived Alzheimer’s Disease Model Neurons. Biol. Pharm. Bull. 2018, 41, 451–457. [Google Scholar] [CrossRef]
  121. Sawmiller, D.; Habib, A.; Li, S.; Darlington, D.; Hou, H.; Tian, J.; Shytle, R.D.; Smith, A.; Giunta, B.; Mori, T.; et al. Diosmin reduces cerebral Aβ levels, tau hyperphosphorylation, neuroinflammation, and cognitive impairment in the 3xTg-AD mice. J. Neuroimmunol. 2016, 299, 98–106. [Google Scholar] [CrossRef]
  122. Dourado, N.S.; Souza, C.; De Almeida, M.M.A.; Da Silva, A.B.; dos Santos, B.L.; Silva, V.D.A.; De Assis, A.M.; Da Silva, J.S.; Souza, D.O.; Costa, M.D.F.D.; et al. Neuroimmunomodulatory and Neuroprotective Effects of the Flavonoid Apigenin in in vitro Models of Neuroinflammation Associated With Alzheimer’s Disease. Front. Aging Neurosci. 2020, 12, 119. [Google Scholar] [CrossRef] [PubMed]
  123. Alsadat, A.M.; Nikbakht, F.; Nia, H.H.; Golab, F.; Khadem, Y.; Barati, M.; Vazifekhah, S. GSK-3β as a target for apigenin-induced neuroprotection against Aβ 25–35 in a rat model of Alzheimer’s disease. Neuropeptides 2021, 90, 102200. [Google Scholar] [CrossRef] [PubMed]
  124. Huang, D.-S.; Yu, Y.-C.; Wu, C.-H.; Lin, J.-Y. Protective Effects of Wogonin against Alzheimer’s Disease by Inhibition of Amyloidogenic Pathway. Evid. Based Complement. Altern. Med. 2017, 2017, 3545169. [Google Scholar] [CrossRef]
  125. Vedagiri, A.; Thangarajan, S. Mitigating effect of chrysin loaded solid lipid nanoparticles against Amyloid β25–35 induced oxidative stress in rat hippocampal region: An efficient formulation approach for Alzheimer’s disease. Neuropeptides 2016, 58, 111–125. [Google Scholar] [CrossRef]
  126. Giacomeli, R.; de Gomes, M.G.; Reolon, J.B.; Haas, S.E.; Colomé, L.M.; Jesse, C.R. Chrysin loaded lipid-core nanocapsules ameliorates neurobehavioral alterations induced by β-amyloid1-42 in aged female mice. Behav. Brain Res. 2020, 390, 112696. [Google Scholar] [CrossRef]
  127. Beg, T.; Jyoti, S.; Naz, F.; Rahul; Ali, F.; Ali, S.K.; Reyad, A.M.; Siddique, Y.H. Protective Effect of Kaempferol on the Transgenic Drosophila Model of Alzheimer’s Disease. CNS Neurol. Disord.-Drug Targets 2018, 17, 421–429. [Google Scholar] [CrossRef]
  128. Paula, P.-C.; Maria, S.-G.A.; Luis, C.-H.; Patricia, C.-G.G. Preventive Effect of Quercetin in a Triple Transgenic Alzheimer’s Disease Mice Model. Molecules 2019, 24, 2287. [Google Scholar] [CrossRef]
  129. Mohammadi, N.; Asle-Rousta, M.; Rahnema, M.; Amini, R. Morin attenuates memory deficits in a rat model of Alzheimer’s disease by ameliorating oxidative stress and neuroinflammation. Eur. J. Pharmacol. 2021, 910, 174506. [Google Scholar] [CrossRef]
  130. Huang, L.; Lin, M.; Zhong, X.; Yang, H.; Deng, M. Galangin decreases p-tau, Aβ42 and β-secretase levels, and suppresses autophagy in okadaic acid-induced PC12 cells via an Akt/GSK3β/mTOR signaling-dependent mechanism. Mol. Med. Rep. 2019, 19, 1767–1774. [Google Scholar] [CrossRef]
  131. Ahmad, A.; Ali, T.; Park, H.Y.; Badshah, H.; Rehman, S.U.; Kim, M.O. Neuroprotective Effect of Fisetin Against Amyloid-Beta-Induced Cognitive/Synaptic Dysfunction, Neuroinflammation, and Neurodegeneration in Adult Mice. Mol. Neurobiol. 2017, 54, 2269–2285. [Google Scholar] [CrossRef]
  132. Thummayot, S.; Tocharus, C.; Jumnongprakhon, P.; Suksamrarn, A.; Tocharus, J. Cyanidin attenuates Aβ25-35-induced neuroinflammation by suppressing NF-κB activity downstream of TLR4/NOX4 in human neuroblastoma cells. Acta Pharmacol. Sin. 2018, 39, 1439–1452. [Google Scholar] [CrossRef] [PubMed]
  133. Sohanaki, H.; Baluchnejadmojarad, T.; Nikbakht, F.; Roghani, M. Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer’s disease by inhibition of glial activation, cholinesterase, and oxidative stress. Biomed. Pharmacother. 2016, 83, 85–91. [Google Scholar] [CrossRef] [PubMed]
  134. Shahidi, S.; Alisavari, N.; Soleimani-Asl, S.; Zarei, M.; Hashemi-Firouzi, N. Protective effect of chronic administration of pelargonidin on neuronal apoptosis and memory process in amyloid-beta-treated rats. Avicenna J. Phytomed. 2021, 11, 407–416. [Google Scholar] [CrossRef]
  135. Bonet-Costa, V.; Herranz-Pérez, V.; Blanco-Gandía, M.; Mas-Bargues, C.; Inglés, M.; Garcia-Tarraga, P.; Rodriguez-Arias, M.; Miñarro, J.; Borras, C.; Garcia-Verdugo, J.M.; et al. Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer’s Disease. J. Alzheimer’s Dis. 2016, 51, 701–711. [Google Scholar] [CrossRef]
  136. Gutierrez-Zepeda, A.; Santell, R.; Wu, Z.; Brown, M.; Wu, Y.; Khan, I.; Link, C.D.; Zhao, B.; Luo, Y. Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC Neurosci. 2005, 6, 54. [Google Scholar] [CrossRef]
  137. Wei, J.; Yang, F.; Gong, C.; Shi, X.; Wang, G. Protective effect of daidzein against streptozotocin-induced Alzheimer’s disease via improving cognitive dysfunction and oxidative stress in rat model. J. Biochem. Mol. Toxicol. 2019, 33, e22319. [Google Scholar] [CrossRef]
  138. Tsai, M.-C.; Lin, S.-H.; Hidayah, K.; Lin, C.-I. Equol Pretreatment Protection of SH-SY5Y Cells against Aβ (25–35)-Induced Cytotoxicity and Cell-Cycle Reentry via Sustaining Estrogen Receptor Alpha Expression. Nutrients 2019, 11, 2356. [Google Scholar] [CrossRef]
  139. Kim, S.-K.; Ko, Y.-H.; Lee, Y.; Lee, S.-Y.; Jang, C.-G. Antineuroinflammatory Effects of 7,3’,4’-Trihydroxyisoflavone in Lipopolysaccharide-Stimulated BV2 Microglial Cells through MAPK and NF-κB Signaling Suppression. Biomol. Ther. 2021, 29, 127–134. [Google Scholar] [CrossRef]
  140. Vepsäläinen, S.; Koivisto, H.; Pekkarinen, E.; Mäkinen, P.; Dobson, G.; McDougall, G.J.; Stewart, D.; Haapasalo, A.; Karjalainen, R.O.; Tanila, H.; et al. Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimer’s disease. J. Nutr. Biochem. 2013, 24, 360–370. [Google Scholar] [CrossRef]
  141. Wang, J.; Ho, L.; Zhao, W.; Ono, K.; Rosensweig, C.; Chen, L.; Humala, N.; Teplow, D.B.; Pasinetti, G.M. Grape-Derived Polyphenolics Prevent A Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer’s Disease. J. Neurosci. 2008, 28, 6388–6392. [Google Scholar] [CrossRef]
  142. Wang, Y.-J.; Thomas, P.; Zhong, J.-H.; Bi, F.-F.; Kosaraju, S.; Pollard, A.; Fenech, M.; Zhou, X.-F. Consumption of Grape Seed Extract Prevents Amyloid-β Deposition and Attenuates Inflammation in Brain of an Alzheimer’s Disease Mouse. Neurotox. Res. 2009, 15, 3–14. [Google Scholar] [CrossRef] [PubMed]
  143. Augustin, S.; Rimbach, G.; Augustin, K.; Schliebs, R.; Wolffram, S.; Cermak, R. Effect of a short- and long-term treatment with Ginkgo biloba extract on Amyloid Precursor Protein Levels in a transgenic mouse model relevant to Alzheimer’s disease. Arch. Biochem. Biophys. 2009, 481, 177–182. [Google Scholar] [CrossRef]
  144. Rezai-Zadeh, K.; Shytle, D.; Sun, N.; Mori, T.; Hou, H.; Jeanniton, D.; Ehrhart, J.; Townsend, K.; Zeng, J.; Morgan, D.; et al. Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice. J. Neurosci. 2005, 25, 8807–8814. [Google Scholar] [CrossRef] [PubMed]
  145. Rezai-Zadeh, K.; Arendash, G.W.; Hou, H.; Fernandez, F.; Jensen, M.; Runfeldt, M.; Shytle, R.D.; Tan, J. Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 2008, 1214, 177–187. [Google Scholar] [CrossRef] [PubMed]
  146. E Ehrnhoefer, D.; Bieschke, J.; Boeddrich, A.; Herbst, M.; Masino, L.; Lurz, R.; Engemann, S.; Pastore, A.; E Wanker, E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 2008, 15, 558–566. [Google Scholar] [CrossRef]
  147. Bieschke, J.; Russ, J.; Friedrich, R.P.; Ehrnhoefer, D.E.; Wobst, H.; Neugebauer, K.; Wanker, E.E. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. USA 2010, 107, 7710–7715. [Google Scholar] [CrossRef]
  148. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer’s disease. J. Neurochem. 2003, 87, 172–181. [Google Scholar] [CrossRef]
  149. Hirohata, M.; Hasegawa, K.; Tsutsumi-Yasuhara, S.; Ohhashi, Y.; Ookoshi, T.; Ono, K.; Yamada, M.; Naiki, H. The Anti-Amyloidogenic Effect Is Exerted against Alzheimer’s β-Amyloid Fibrils in Vitro by Preferential and Reversible Binding of Flavonoids to the Amyloid Fibril Structure. Biochemistry 2007, 46, 1888–1899. [Google Scholar] [CrossRef]
  150. Ushikubo, H.; Watanabe, S.; Tanimoto, Y.; Abe, K.; Hiza, A.; Ogawa, T.; Asakawa, T.; Kan, T.; Akaishi, T. 3,3′,4′,5,5′-Pentahydroxyflavone is a potent inhibitor of amyloid β fibril formation. Neurosci. Lett. 2012, 513, 51–56. [Google Scholar] [CrossRef]
  151. Murakami, K.; Irie, K. Three Structural Features of Functional Food Components and Herbal Medicine with Amyloid β42 Anti-Aggregation Properties. Molecules 2019, 24, 2125. [Google Scholar] [CrossRef]
  152. Rios, M.A.M.; Toral-Rios, D.; Franco-Bocanegra, D.; Villeda-Hernández, J.; Campos-Peña, V. Inflammatory process in Alzheimer’s Disease. Front. Integr. Neurosci. 2013, 7, 59. [Google Scholar] [CrossRef] [Green Version]
  153. Serafini, M.; Peluso, I.; Raguzzini, A. Flavonoids as anti-inflammatory agents. Proc. Nutr. Soc. 2010, 69, 273–278. [Google Scholar] [CrossRef] [PubMed]
  154. Hodgson, J.; Puddey, I.; Mori, T.; Burke, V.; Baker, R.; Beilin, L. Effects of regular ingestion of black tea on haemostasis and cell adhesion molecules in humans. Eur. J. Clin. Nutr. 2001, 55, 881–886. [Google Scholar] [CrossRef] [PubMed]
  155. Murphy, K.J.; Chronopoulos, A.K.; Singh, I.; A Francis, M.; Moriarty, H.; Pike, M.J.; Turner, A.H.; Mann, N.J.; Sinclair, A.J. Dietary flavanols and procyanidin oligomers from cocoa (Theobroma cacao) inhibit platelet function. Am. J. Clin. Nutr. 2003, 77, 1466–1473. [Google Scholar] [CrossRef]
  156. Steptoe, A.; Gibson, L.; Vuononvirta, R.; Hamer, M.; Wardle, J.; Rycroft, J.A.; Martin, J.F.; Erusalimsky, J. The effects of chronic tea intake on platelet activation and inflammation: A double-blind placebo controlled trial. Atherosclerosis 2007, 193, 277–282. [Google Scholar] [CrossRef] [PubMed]
  157. Estruch, R.; Sacanella, E.; Badia, E.; Antúnez, E.; Nicolás, J.M.; Fernández-Solá, J.; Rotilio, D.; de Gaetano, G.; Rubin, E.; Urbano-Márquez, A. Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: A prospective randomized crossover trial: Effects of wine on inflammatory markers. Atherosclerosis 2004, 175, 117–123. [Google Scholar] [CrossRef]
  158. Spagnuolo, C.; Moccia, S.; Russo, G.L. Anti-inflammatory effects of flavonoids in neurodegenerative disorders. Eur. J. Med. Chem. 2018, 153, 105–115. [Google Scholar] [CrossRef]
  159. Kurumbail, R.G.; Stevens, A.M.; Gierse, J.K.; McDonald, J.J.; Stegeman, R.A.; Pak, J.Y.; Gildehaus, D.; Iyashiro, J.M.; Penning, T.D.; Seibert, K.; et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644–648. [Google Scholar] [CrossRef]
  160. Higgins, A.J.; Lees, P. The acute inflammatory process, arachidonic acid metabolism and the mode of action of anti-inflammatory drugs. Equine Vet. J. 1984, 16, 163–175. [Google Scholar] [CrossRef]
  161. Madeswaran, A. In-silico docking studies of cyclooxygenase inhibitory activity of commercially available flavonoids. Asian J. Pharm. Life Sci. 2013, 174–181. [Google Scholar]
  162. Madeswaran, A.; Umamaheswari, M.; Asokkumar, K.; Sivashanmugam, T.; SubhadraDevi, V.; Jagannath, P. In silico docking studies of phosphodiesterase inhibitory activity of commercially available flavonoids. Orient. Pharm. Exp. Med. 2012, 12, 301–306. [Google Scholar] [CrossRef]
  163. Ribeiro, D.; Freitas, M.; Tomé, S.M.; Silva, A.M.; Porto, G.; Cabrita, E.J.; Marques, M.M.B.; Fernandes, E. Inhibition of LOX by flavonoids: A structure–activity relationship study. Eur. J. Med. Chem. 2014, 72, 137–145. [Google Scholar] [CrossRef]
  164. Kim, H.K.; Cheon, B.S.; Kim, Y.H.; Kim, S.Y.; Kim, H.P. Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264.7 and their structure–activity relationships. Biochem. Pharmacol. 1999, 58, 759–765. [Google Scholar] [CrossRef]
  165. Santangelo, C.; Vari, R.; Scazzocchio, B.; Di Benedetto, R.; Filesi, C.; Masella, R. Polyphenols, intracellular signalling and inflammation. Ann. Istituto Super. Sanita 2007, 43, 394–405. [Google Scholar]
  166. Geng, Y.; Zhang, B.; Lotz, M. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. J. Immunol. 1993, 151, 6692–6700. [Google Scholar]
  167. Cho, J.Y.; Kim, P.S.; Park, J.; Yoo, E.S.; Baik, K.U.; Kim, Y.-K.; Park, M.H. Inhibitor of tumor necrosis factor-α production in lipopolysaccharide-stimulated RAW264.7 cells from Amorpha fruticosa. J. Ethnopharmacol. 2000, 70, 127–133. [Google Scholar] [CrossRef]
  168. Wadsworth, T.L.; McDonald, T.L.; Koop, D.R. Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor necrosis factor-α. Biochem. Pharmacol. 2001, 62, 963–974. [Google Scholar] [CrossRef]
  169. Hanasaki, Y.; Ogawa, S.; Fukui, S. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic. Biol. Med. 1994, 16, 845–850. [Google Scholar] [CrossRef]
  170. Bors, W.; Heller, W.; Michel, C.; Saran, M. [36] Flavonoids as antioxidants: Determination of radical-scavenging efficiencies. In Methods in Enzymology; Academic Press: Cambridge, MA, USA, 1990; Volume 186, pp. 343–355. [Google Scholar] [CrossRef]
  171. Chang, W.S.; Lee, Y.J.; Lu, F.J.; Chiang, H.C. Inhibitory effects of flavonoids on xanthine oxidase. Anticancer. Res. 1993, 13, 2165–2170. [Google Scholar]
  172. Cos, P.; Ying, L.; Calomme, M.; Hu, J.P.; Cimanga, K.; Van Poel, B.; Pieters, L.; Vlietinck, A.A.J.; Berghe, D.V. Structure−Activity Relationship and Classification of Flavonoids as Inhibitors of Xanthine Oxidase and Superoxide Scavengers. J. Nat. Prod. 1998, 61, 71–76. [Google Scholar] [CrossRef]
  173. Ferrali, M.; Signorini, C.; Caciotti, B.; Sugherini, L.; Ciccoli, L.; Giachetti, D.; Comporti, M. Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity. FEBS Lett. 1997, 416, 123–129. [Google Scholar] [CrossRef]
  174. Remigante, A.; Spinelli, S.; Basile, N.; Caruso, D.; Falliti, G.; Dossena, S.; Marino, A.; Morabito, R. Oxidation Stress as a Mechanism of Aging in Human Erythrocytes: Protective Effect of Quercetin. Int. J. Mol. Sci. 2022, 23, 7781. [Google Scholar] [CrossRef] [PubMed]
  175. Jasenovec, T.; Radosinska, D.; Kollarova, M.; Balis, P.; Ferenczyova, K.; Kalocayova, B.; Bartekova, M.; Tothova, L.; Radosinska, J. Beneficial Effect of Quercetin on Erythrocyte Properties in Type 2 Diabetic Rats. Molecules 2021, 26, 4868. [Google Scholar] [CrossRef] [PubMed]
  176. Rodríguez-Arce, E.; Saldías, M. Antioxidant properties of flavonoid metal complexes and their potential inclusion in the development of novel strategies for the treatment against neurodegenerative diseases. Biomed. Pharmacother. 2021, 143, 112236. [Google Scholar] [CrossRef] [PubMed]
  177. Chlebda, E.; Magdalan, J.; Merwid-Ląd, A.; Trocha, M.; Kopacz, M.; Kuźniar, A.; Nowak, D.; Szeląg, A. Influence of water-soluble flavonoids, quercetin-5′-sulfonic acid sodium salt and morin-5′-sulfonic acid sodium salt, on antioxidant parameters in the subacute cadmium intoxication mouse model. Exp. Toxicol. Pathol. 2010, 62, 105–108. [Google Scholar] [CrossRef]
  178. Simunkova, M.; Barbierikova, Z.; Jomova, K.; Hudecova, L.; Lauro, P.; Alwasel, S.; Alhazza, I.; Rhodes, C.; Valko, M. Antioxidant vs. Prooxidant Properties of the Flavonoid, Kaempferol, in the Presence of Cu(II) Ions: A ROS-Scavenging Activity, Fenton Reaction and DNA Damage Study. Int. J. Mol. Sci. 2021, 22, 1619. [Google Scholar] [CrossRef]
  179. Wang, Z.H.; Kang, K.A.; Zhang, R.; Piao, M.J.; Jo, S.H.; Kim, J.S.; Kang, S.S.; Lee, J.S.; Park, D.H.; Hyun, J.W. Myricetin suppresses oxidative stress-induced cell damage via both direct and indirect antioxidant action. Environ. Toxicol. Pharmacol. 2010, 29, 12–18. [Google Scholar] [CrossRef]
  180. Ahmed, O.M.; Ahmed, A.A.; Fahim, H.I.; Zaky, M.Y. Quercetin and naringenin abate diethylnitrosamine/acetylaminofluorene-induced hepatocarcinogenesis in Wistar rats: The roles of oxidative stress, inflammation and cell apoptosis. Drug Chem. Toxicol. 2019, 45, 262–273. [Google Scholar] [CrossRef]
  181. Goudarzi, M.; Kalantar, M.; Sadeghi, E.; Karamallah, M.H.; Kalantar, H. Protective effects of apigenin on altered lipid peroxidation, inflammation, and antioxidant factors in methotrexate-induced hepatotoxicity. Naunyn-Schmiedebergs Arch. fur Exp. Pathol. und Pharmakol. 2021, 394, 523–531. [Google Scholar] [CrossRef]
  182. DeToma, A.S.; Choi, J.-S.; Braymer, J.J.; Lim, M.H. Myricetin: A Naturally Occurring Regulator of Metal-Induced Amyloid-β Aggregation and Neurotoxicity. ChemBioChem 2011, 12, 1198–1201. [Google Scholar] [CrossRef]
  183. Hyung, S.-J.; DeToma, A.S.; Brender, J.R.; Lee, S.; Vivekanandan, S.; Kochi, A.; Choi, J.-S.; Ramamoorthy, A.; Ruotolo, B.T.; Lim, M.H. Insights into antiamyloidogenic properties of the green tea extract (−)-epigallocatechin-3-gallate toward metal-associated amyloid-β species. Proc. Natl. Acad. Sci. USA 2013, 110, 3743–3748. [Google Scholar] [CrossRef] [PubMed]
  184. DeToma, A.S.; Krishnamoorthy, J.; Nam, Y.; Lee, H.J.; Brender, J.R.; Kochi, A.; Lee, D.; Onnis, V.; Congiu, C.; Manfredini, S.; et al. Interaction and reactivity of synthetic aminoisoflavones with metal-free and metal-associated amyloid-β. Chem. Sci. 2014, 5, 4851–4862. [Google Scholar] [CrossRef] [PubMed]
  185. Mira, L.; Fernandez, M.T.; Santos, M.; Rocha, R.; Florêncio, M.H.; Jennings, K.R. Interactions of Flavonoids with Iron and Copper Ions: A Mechanism for their Antioxidant Activity. Free Radic. Res. 2002, 36, 1199–1208. [Google Scholar] [CrossRef]
  186. Van Acker, S.A.B.E.; Van Den Berg, D.-J.; Tromp, M.N.J.L.; Griffioen, D.H.; Van Bennekom, W.P.; Van Der Vijgh, W.J.F.; Bast, A. Structural aspects of antioxidant activity of flavonoids. Free Radic. Biol. Med. 1996, 20, 331–342. [Google Scholar] [CrossRef]
  187. Perry, E.K.; E Tomlinson, B.; Blessed, G.; Bergmann, K.; Gibson, P.H.; Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978, 2, 1457–1459. [Google Scholar] [CrossRef] [PubMed]
  188. Noui, A.; Boudiar, T.; Boulebd, H.; Gali, L.; Contreras, M.D.M.; Segura-Carretero, A.; Nieto, G.; Akkal, S. HPLC–DAD–ESI/MS profiles of bioactive compounds, antioxidant and anticholinesterase activities of Ephedra alata subsp. alenda growing in Algeria. Nat. Prod. Res. 2022, 1–6. [Google Scholar] [CrossRef]
  189. Khare, N.; Maheshwari, S.K.; Jha, A.K. Screening and identification of secondary metabolites in the bark of Bauhinia variegata to treat Alzheimer’s disease by using molecular docking and molecular dynamics simulations. J. Biomol. Struct. Dyn. 2021, 39, 5988–5998. [Google Scholar] [CrossRef]
  190. Khan, M.T.H.; Orhan, I.; Şenol, F.; Kartal, M.; Şener, B.; Dvorská, M.; Šmejkal, K.; Šlapetová, T. Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies. Chem. Interactions 2009, 181, 383–389. [Google Scholar] [CrossRef]
  191. Zhao, L.; Shu-Ping, X.U.; Zong-Yang, L.I.; Zhang, L.; Zhang, Z.S.; Pan, R.L. Study on the antioxidant and antiacetylcholinesterase activities of myricitrin and its structure-similar compounds. Sci. Technol. Food Ind. 2012, 33, 56–58+62. [Google Scholar]
  192. Wang, B.; Zhong, Y.; Gao, C.; Li, J. Myricetin ameliorates scopolamine-induced memory impairment in mice via inhibiting acetylcholinesterase and down-regulating brain iron. Biochem. Biophys. Res. Commun. 2017, 490, 336–342. [Google Scholar] [CrossRef]
  193. Sun, C.; Yin, Z.; Chen, J.; Wang, W.; Zheng, G.; Li, J.; Chen, L.; Zhang, Q. Dihydromyricetin Improves Cognitive Impairments in d -Galactose-Induced Aging Mice through Regulating Oxidative Stress and Inhibition of Acetylcholinesterase. Mol. Nutr. Food Res. 2022, 66, e2101002. [Google Scholar] [CrossRef] [PubMed]
  194. Das, S.; Laskar, M.A.; Sarker, S.D.; Choudhury, M.D.; Choudhury, P.R.; Mitra, A.; Jamil, S.; Lathiff, S.M.A.; Abdullah, S.A.; Basar, N.; et al. Prediction of Anti-Alzheimer’s Activity of Flavonoids Targeting Acetylcholinesterase in silico. Phytochem. Anal. 2017, 28, 324–331. [Google Scholar] [CrossRef] [PubMed]
  195. Li, M.; Xu, Z. Quercetin in a lotus leaves extract may be responsible for antibacterial activity. Arch. Pharmacal Res. 2008, 31, 640–644. [Google Scholar] [CrossRef]
  196. Grenier, D.; Chen, H.; Ben Lagha, A.; Fournier-Larente, J.; Morin, M.-P. Dual Action of Myricetin on Porphyromonas gingivalis and the Inflammatory Response of Host Cells: A Promising Therapeutic Molecule for Periodontal Diseases. PLoS ONE 2015, 10, e0131758. [Google Scholar] [CrossRef] [PubMed]
  197. Ono, K.; Nakane, H.; Fukushima, M.; Chermann, J.-C.; Barre-Sinoussi, F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. JBIC J. Biol. Inorg. Chem. 1990, 190, 469–476. [Google Scholar] [CrossRef] [PubMed]
  198. Brinkworth, R.I.; Stoermer, M.; Fairlie, D. Flavones are inhibitors of HIV-1 proteinase. Biochem. Biophys. Res. Commun. 1992, 188, 631–637. [Google Scholar] [CrossRef]
  199. Fesen, M.R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K.W. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595–608. [Google Scholar] [CrossRef]
  200. Kim, H.J.; Woo, E.-R.; Shin, A.C.-G.; Park, H. A New Flavonol Glycoside Gallate Ester from Acer okamotoanum and Its Inhibitory Activity against Human Immunodeficiency Virus-1 (HIV-1) Integrase. J. Nat. Prod. 1998, 61, 145–148. [Google Scholar] [CrossRef]
  201. Kaul, T.N.; Middleton, E.; Ogra, P.L. Antiviral effect of flavonoids on human viruses. J. Med Virol. 1985, 15, 71–79. [Google Scholar] [CrossRef]
  202. Cushnie, T.P.T.; Lamb, A.J. Antimicrobial activity of flavonoids. Int. J. Antimicrob. Agents 2005, 26, 343–356. [Google Scholar] [CrossRef]
  203. Lyu, S.Y.; Rhim, J.Y.; Park, W.B. Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)in vitro. Arch. Pharm. Res. 2005, 28, 1293–1301. [Google Scholar] [CrossRef] [PubMed]
Ijms 23 10020 g001 550
Figure 1. Mechanism of AD pathogenesis. AD is a disease caused by multiple factors, such as Aβ accumulation, hyperphosphorylated tau, oxidative stress, inflammation, metal imbalance, etc. These factors promote one another and form a feedback loop mechanism. Among all the factors, Aβ accumulation and hyperphosphorylated tau are the two main diagnostic indicators of AD and are the main substances that cause the occurrence of AD.
Figure 1. Mechanism of AD pathogenesis. AD is a disease caused by multiple factors, such as Aβ accumulation, hyperphosphorylated tau, oxidative stress, inflammation, metal imbalance, etc. These factors promote one another and form a feedback loop mechanism. Among all the factors, Aβ accumulation and hyperphosphorylated tau are the two main diagnostic indicators of AD and are the main substances that cause the occurrence of AD.
Ijms 23 10020 g001
Ijms 23 10020 g002 550
Figure 2. Chemical structures of various classes of flavonoids. Flavonoids have the basic configuration of C6-C3-C6. According to the structure of the C ring attached to the A and B rings and the unsaturation of the C ring, they can be divided into: flavones, flavanones, isoflavones, flavonols or flavan, and anthocyanins.
Figure 2. Chemical structures of various classes of flavonoids. Flavonoids have the basic configuration of C6-C3-C6. According to the structure of the C ring attached to the A and B rings and the unsaturation of the C ring, they can be divided into: flavones, flavanones, isoflavones, flavonols or flavan, and anthocyanins.
Ijms 23 10020 g002
Ijms 23 10020 g003 550
Figure 3. Flavonoids exert anti-AD effects by interacting with Aβ. Flavonoids exert anti-amyloidogenic effects through: (1) decreasing the levels of APP; (2) reducing Aβ production by regulating APP processing; and (3) preventing the aggregation of Aβ. The structural characteristics for inhibitory activity against the aggregation of Aβ include a catechol group and in the B ring and a 2,3-double bond in the C ring. The double red line represents the inhibitory effect, and the green arrow represents the promoting effect.
Figure 3. Flavonoids exert anti-AD effects by interacting with Aβ. Flavonoids exert anti-amyloidogenic effects through: (1) decreasing the levels of APP; (2) reducing Aβ production by regulating APP processing; and (3) preventing the aggregation of Aβ. The structural characteristics for inhibitory activity against the aggregation of Aβ include a catechol group and in the B ring and a 2,3-double bond in the C ring. The double red line represents the inhibitory effect, and the green arrow represents the promoting effect.
Ijms 23 10020 g003
Table
Table 1. Structure of flavonoids in the text.
Table 1. Structure of flavonoids in the text.
  • Catechins
Ijms 23 10020 i001
2.
Quercetin
Ijms 23 10020 i002
3.
Apigenin
Ijms 23 10020 i003
4.
Nobiletin
Ijms 23 10020 i004
5.
Fisetin
Ijms 23 10020 i005
6.
Chrysin
Ijms 23 10020 i006
7.
(−)-Epicatechin
Ijms 23 10020 i007
8.
Kaempferol
Ijms 23 10020 i008
9.
Isorhamnetin
Ijms 23 10020 i009
10.
Morin
Ijms 23 10020 i010
11.
Myricetin
Ijms 23 10020 i011
12.
Wogonin
Ijms 23 10020 i012
13.
Silybin
Ijms 23 10020 i013
14.
Galangin
Ijms 23 10020 i014
15.
Hesperetin
Ijms 23 10020 i015
16.
Genistein
Ijms 23 10020 i016
17.
Daidzein
Ijms 23 10020 i017
18.
Taxifolin
Ijms 23 10020 i018
19.
Naringenin
Ijms 23 10020 i019
20.
Daidzein
Ijms 23 10020 i020
21.
Baicalein
Ijms 23 10020 i021
22.
Epigallocatechin-3-gallate
Ijms 23 10020 i022
23.
Luteolin
Ijms 23 10020 i023
24.
Dihydroxymyricetin
Ijms 23 10020 i024
25.
5,7-dihydroxy-4′-methoxy-8-prenylflavanone
Ijms 23 10020 i025
26.
Quercetagetin
Ijms 23 10020 i026
27.
Hinokiflavone
Ijms 23 10020 i027
28.
Robinetin
Ijms 23 10020 i028
29.
Epigallocatechin
Ijms 23 10020 i029
30.
Tangeritin
Ijms 23 10020 i030
31.
Rhamnetin
Ijms 23 10020 i031
32.
Pachypodol
Ijms 23 10020 i032
33.
Homoeriodictyol
Ijms 23 10020 i033
34.
Aromadedrin
Ijms 23 10020 i034
35.
Glycitein
Ijms 23 10020 i035
36.
Pelargonidin
Ijms 23 10020 i036
Table
Table 2. Favorable effects of flavonoids against different AD targets in silico.
Table 2. Favorable effects of flavonoids against different AD targets in silico.
ClassFlavonoidsAD TargetsLigand–Receptor InteractionsReferences
Flavanols(−)-Epigallocatechin (EGC)AChEHydrogen bonding[82,83]
BChE
GSK-3β
γ-secretase[83]
BACE-1
Epicatechin-3-O-gallateAChEHydrogen bonding[82]
BChE
(−)-Epicatechin (EPC)AChEHydrogen bonding[83]
BChE
GSK-3β
γ-secretase
BACE-1
(−)-Epigallocatechin gallate (EGCG)AChEHydrogen bonding[82,83]
Flavanols(−)-Epigallocatechin gallate (EGCG)BChE
GSK-3β[83]
γ-secretase
BACE-1
(+)-Catechin (CAT)AChEHydrogen bonding[82,83]
BChE
GSK-3β
γ-secretase[83]
BACE-1
ArtoflavanocoumarinBACE-1Hydrogen bonding; hydrophobic interactions[84]
FlavanolsEpicatechin Gallate(ECG)ApoE4Hydrogen bonding; hydrophobic interactions[85]
FlavanonesCudraflavanone BPTGS2Hydrogen bonding[86]
HesperidinBACE-1Hydrogen bonding[87]
AChE
BChE
KolavironAβ42 fibrilsHydrogen bonding; hydrophobic interactions[88]
Macaflavanone CGSAPHydrogen bonding; hydrophobic interactions[89]
NaringeninAChEHydrogen bonding[87]
PinocembrinBACE-1Hydrogen bonding[90]
FlavanonesPinostrobinBACE-1Hydrogen bonding[90]
SilibininAChEHydrogen bonding; π-π and π-H interaction[91]
Aβ42Hydrophobic interactions
Taxifolinα-amylaseHydrogen bonding; π-π interaction[92]
FlavonesApigeninBACE-1Hydrogen bonding[93]
Aβ42 fibrils[94]
BaicaleinBACE-1Hydrogen bonding; hydrophobic interactions[95]
AChE
IsovitexinAChEHydrogen bonding[96]
FlavonesLinarinAChEHydrogen bonding; π-π interaction[97]
VitexinAChEHydrogen bonding[96]
Vitexin-4-O-glucosideAChEHydrogen bonding[96]
ChrysinAChEHydrogen bonding; π-π interaction; hydrophobic interactions[98]
BACE-1Hydrogen bonding; hydrophobic interactions[99]
MAO-B
Flavonols2-(4′ Benzyloxyphenyl)-3-hydroxychromen-4-oneβ-amyloid fibrilHydrogen bonding[100]
Flavonols2-(4′ Benzyloxyphenyl)-3-hydroxychromen-4-oneβ-amyloidHydrogen bonding; hydrophobic interactions[100]
8-PrenylkaempferolPTGS2Hydrogen bonding[86]
IcariinAChE-[101]
NMDAR-
PDE5-
KaempherolBACE-1Hydrogen bonding[93]
MorinAβ42 protofibrilHydrogen bonding; hydrophobic interactions; aromatic stacking interactions[102]
FlavonolsMorinBACE-1Hydrogen bonding[93]
FlavonolsMyricetinBACE-1Hydrogen bonding[93]
QuercetinAChEHydrogen bonding[103]
BACE-1[93]
Aβ42 fibrils[94]
FisetinAChEHydrogen bonding[104]
IsoflavonesGenisteinBACE-1Hydrogen bonding[105]
IsoflavonesGenisteinAChEHydrogen bonding; hydrophobic interactions[106]
BChE
NMDAR
PuerarinAChEHydrogen bonding[107]
COX-2
C3
CaMK IIα[108]
Table
Table 3. Classification and promising preclinical studies of flavonoids and their neuroprotective role against Alzheimer’s disease.
Table 3. Classification and promising preclinical studies of flavonoids and their neuroprotective role against Alzheimer’s disease.
ClassFlavonoidsEffectsModelReferences
FlavanonesNaringinAttenuates oxido-nitrosative stress and inflammationICV-STZ-induced rats[109]
Regulates multiple pathways, including amyloid β metabolism, tau protein hyperphosphorylation, acetylcholinergic system, glutamate receptor system, oxidative stress, and cell apoptosisHydrocortisone-induced mice[110]
HesperetinMultipotent effect, involving the inhibition of oxidative stress, and neuroinflammationC57BL/6N mice treated with Aβ1–42[111]
EriodictyolAttenuates neuroinflammation and
amyloidogenesis		LPS-induced C57BL/6J mice model and BV2 microglial cells[112]
FlavanolsEpigallocatechin-3-gallateDecreased the hyperphosphorylation of tau, suppressed BACE1 expression and activity as well as the expression of Aβ1–42, and promoted Ach content by diminishing the activity of AchEAD rat models through an injection with Aβ 25–35 solution[113]
EpigallocatechinAlleviate Aβ40 aggregation and diminish ROS production, reduce the Aβ plaques in the brainNeuroblastoma cells treated with Aβ40/APP/PS1 mouse[114]
(−)-EpicatechinReduces Aβ levels by inhibiting β, γ-secretaseTASTPM transgenic mouse model[115]
Inhibits tau phosphorylationrTg4510 mouse model[116]
FlavanolsCatechinsDecrease Aβ42 production, APP-C99/89 expression, γ-secretase component and Wnt protein levels, and γ-secretase activity, and increases the levels of APP-C83 protein and enzyme activities (α-secretase, neprilysin and Pin1)NSE/hAPP-C105 Tg mice[117]
FlavonesLuteolinDecrease in the expression of Aβ42 aggregated, the oxidative stress, and apoptotic markersTransgenic flies expressing human Aβ42 peptides[118]
NobiletinImproves cognitive impairment and reduces soluble Aβ levels3xTg-AD mice model[119]
Reduces intracellular and extracellular β-AmyloidiPS cells[120]
FlavonesDiosminReduces cerebral Aβ levels, tau hyperphosphorylation, and neuroinflammation3xTg-AD mice model[121]
ApigeninPreserves neuron and astrocyte morphology and reduces inflammation by regulating the expression of inflammatory mediatorsLPS induced neuron/glial cells or neuron/glial cells treated with Aβ1–42[122]
Decreases the expression of GSK-3β with the consequence of lowering the hyperphosphorylation of tau protein and suppresses BACE1 expressionWistar rats treated with Aβ 25–35[123]
FlavonesWogoninAttenuates amyloidogenic pathway by decreasing the levels of BACE1, APP β-C-terminal fragment, Aβ-aggregation, and phosphorylated tau3xTg-AD mice model[124]
ChrysinAttenuated Aβ-induced memory impairment through the reduction of lipid peroxidation levels and the elevation of antioxidant moleculesSprague–Dawley rats treated with Aβ25–35[125]
Reverse learning impairment, reduced neuroinflammation induced by Aβ by lowering the expressions of IL-1, IL-10, and TNF-1 in the brainSwiss mice treated with Aβ1–42[126]
FlavonolsKaempferolReduced the oxidative stress and acetylcholinesterase activityTransgenic flies expressing human Aβ42 peptides[127]
FlavonolsQuercetinReduces Aβ protein and tauopathy in hippocampus and amygdala3xTg-AD mice model[128]
MorinAmeliorates oxidative stress and neuroinflammationWistar rats treated with Aβ1–42[129]
GalanginDecreases β-secretase, Aβ42, and p-tau levels; suppresses Beclin-1 and p-GSK3β expression; promotes p-Akt and p-mTOR expressionOkadaic-acid-induced PC12 cell[130]
FisetinDecreased the accumulation of Aβ, BACE-1 expression, and hyperphosphorylation of tau protein; increased the levels of both presynaptic and postsynaptic proteins C57BL/6N mice treated with Aβ1–42[131]
AnthocyaninsCyanidinAttenuates Aβ25–35-induced neuroinflammationSK-N-SH cells (human neuroblastoma cell line) treated with Aβ25–35[132]
PelargonidinInhibits of glial activation, cholinesterase, and oxidative stressWistar rats treated with Aβ25–35[133]
Decreases neuronal apoptosisWistar rats treated with Aβ25–35[134]
IsoflavonesGenisteinClears amyloid-β through PPARγ/ApoE activationAPPswe/PS1dE9 mice model[135]
GlyciteinInhibits Abeta deposition and decreases oxidative stressCaenorhabditis elegans (CL2006 and CL4176)[136]
IsoflavonesDaidzeinImproves cognitive dysfunction and oxidative stressICV-STZ-induced rats[137]
EquolReduces Aβ-induced neurotoxicity via sustaining estrogen receptor alpha expressionSH-SY5Y cells treated with Aβ25–35[138]
7,3′,4′-TrihydroxyisoflavoneSuppresses the production of the proinflammatory mediators NO, iNOS, and COX-2 as well as of the proinflammatory cytokineIL-6 and inhibits reactive ROS generationLPS-induced BV2 microglial cells[139]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Li, J.; Sun, M.; Cui, X.; Li, C. Protective Effects of Flavonoids against Alzheimer’s Disease: Pathological Hypothesis, Potential Targets, and Structure–Activity Relationship. Int. J. Mol. Sci. 2022, 23, 10020. https://doi.org/10.3390/ijms231710020

AMA Style

Li J, Sun M, Cui X, Li C. Protective Effects of Flavonoids against Alzheimer’s Disease: Pathological Hypothesis, Potential Targets, and Structure–Activity Relationship. International Journal of Molecular Sciences. 2022; 23(17):10020. https://doi.org/10.3390/ijms231710020

Chicago/Turabian Style

Li, Jiao, Min Sun, Xiaodong Cui, and Chen Li. 2022. "Protective Effects of Flavonoids against Alzheimer’s Disease: Pathological Hypothesis, Potential Targets, and Structure–Activity Relationship" International Journal of Molecular Sciences 23, no. 17: 10020. https://doi.org/10.3390/ijms231710020

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop